WO2024079722A1 - Produits en sachet contenant des capsules - Google Patents

Produits en sachet contenant des capsules Download PDF

Info

Publication number
WO2024079722A1
WO2024079722A1 PCT/IB2023/060370 IB2023060370W WO2024079722A1 WO 2024079722 A1 WO2024079722 A1 WO 2024079722A1 IB 2023060370 W IB2023060370 W IB 2023060370W WO 2024079722 A1 WO2024079722 A1 WO 2024079722A1
Authority
WO
WIPO (PCT)
Prior art keywords
pouched product
acid
composition
weight
nicotine
Prior art date
Application number
PCT/IB2023/060370
Other languages
English (en)
Inventor
Ross Jay Oden
Christopher Keller
My-Linh TRAN
Original Assignee
Nicoventures Trading Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicoventures Trading Limited filed Critical Nicoventures Trading Limited
Publication of WO2024079722A1 publication Critical patent/WO2024079722A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances

Definitions

  • the present disclosure relates to flavored products intended for human use.
  • the products are configured for oral use and deliver substances such as flavors and/or active ingredients during use.
  • Such products may include tobacco or a product derived from tobacco, or may be tobacco-free alternatives.
  • Such products typically contain flavorants and/or active ingredients such as nicotine, caffeine, botanicals, or cannabidiol.
  • the format of such products can vary, and include pouched products containing a powdered or granular composition, lozenges, pastilles, liquids, gels, emulsions, meltable compositions, and the like. See, for example, the types of products described in US Patent App. Pub. Nos.
  • the present disclosure relates to capsules and to compositions and oral products incorporating one or more such capsules.
  • Some such products into which these components are incorporated according to the present disclosure are pouched products including an outer water-permeable pouch defining a cavity containing a composition comprising the one or more capsules and a water-soluble component capable of being released through the water-permeable pouch.
  • the invention includes, without limitation, the following embodiments.
  • Embodiment 1 A pouched product comprising: an outer water-permeable pouch defining a cavity; and a composition adapted for oral use situated within the cavity, wherein the composition comprises one or more rupturable capsules, each rupturable capsule comprising a payload encapsulated within a capsule wall, and wherein the product has a water content of about 20% or less by weight.
  • Embodiment 2 The pouched product of Embodiment 1, wherein the payload comprises a particulate material.
  • Embodiment 3 The pouched product of any of Embodiments 1-2, wherein the payload comprises a liquid in the form of a solution, emulsion, or dispersion.
  • Embodiment 4 The pouched product of Embodiment 3, wherein the liquid comprises water.
  • Embodiment 5 The pouched product of Embodiment 3, wherein the liquid is non-aqueous.
  • Embodiment 6 The pouched product of any of Embodiments 1-5, wherein the payload comprises one or more flavoring agents.
  • Embodiment 7 The pouched product of any of Embodiments 1-6, wherein the payload comprises menthol.
  • Embodiment 8 The pouched product of any of Embodiments 1-7, wherein the payload comprises one or more active ingredients.
  • Embodiment 9 The pouched product of Embodiment 1, wherein the payload consists essentially of water.
  • Embodiment 10 The pouched product of any of Embodiments 1-9, wherein the capsule wall comprises a material selected from the group consisting of a starch, a functional cellulose, a cross-linked polymer, an oil/wax, or any combination thereof.
  • Embodiment 11 The pouched product of any of Embodiments 1-9, wherein the capsule wall comprises an alginate, a hydrogel, a thermoplastic polymer, a biopolymer, a modified starch, a shellac, a sponge, or an acrylate/methacrylate polymer.
  • Embodiment 12 The pouched product of any of Embodiments 1-9, wherein the capsule wall comprises a modified starch.
  • Embodiment 13 The pouched product of Embodiment 12, wherein the modified starch comprises tapioca.
  • Embodiment 14 The pouched product of any of Embodiments 1-9, wherein the capsule wall comprises gelatin.
  • Embodiment 15 The pouched product of Embodiment 1, wherein the payload comprises a flavoring agent and the capsule wall comprises gelatin.
  • Embodiment 16 The pouched product of Embodiment 15, wherein the flavoring agent is menthol.
  • Embodiment 17 The pouched product of Embodiment 1, wherein the payload comprises an air-water emulsion and the capsule wall comprises silica.
  • Embodiment 18 The pouched product of any of Embodiments 1-4 and 6-9, wherein the payload comprises water and the capsule wall comprises sodium alginate and calcium chloride.
  • Embodiment 19 The pouched product of any of Embodiments 1-4 and 6-9, wherein the payload comprises water and the capsule wall comprises a material selected from the group consisting of a starch, a functional cellulose, a cross-linked polymer, an oil/wax, or any combination thereof.
  • Embodiment 20 The pouched product of any of Embodiments 1-4 and 6-19, wherein the payload comprises water and wherein the rupturable capsule further comprises a coating on an exterior surface of the capsule wall.
  • Embodiment 21 The pouched product of Embodiment 20, wherein the coating comprises a material selected from the group consisting of a starch, a functional cellulose, a cross-linked polymer, an oil/wax, or any combination thereof.
  • Embodiment 22 The pouched product of Embodiment 20 or 21, wherein the capsule wall comprises gelatin.
  • Embodiment 23 The pouched product of any of Embodiments 1-22, wherein the one or more rupturable capsules comprises a single rupturable capsule.
  • Embodiment 24 The pouched product of any of Embodiments 1-22, wherein the one or more rupturable capsules comprises a plurality of the rupturable capsules.
  • Embodiment 25 The pouched product of any of Embodiments 1 -24, wherein the one or more rupturable capsules have an average diameter of about 0.5-6 mm.
  • Embodiment 26 The pouched product of any of Embodiments 1-25, wherein the one or more rupturable capsules have an average diameter of about 2.5 to about 4 mm.
  • Embodiment 27 The pouched product of any of Embodiments 1-26, wherein the one or more rupturable capsules have individual weights of about 15 to about 25 mg.
  • Embodiment 28 The pouched product of Embodiment 27, wherein the individual weights are about 20 to about 25 mg.
  • Embodiment 29 The pouched product of any of Embodiments 1-28, wherein the composition is substantially free of a tobacco material other than nicotine, which is optionally included within the composition.
  • Embodiment 30 The pouched product of any of Embodiments 1-29, wherein the composition comprises one or more active ingredients selected from the group consisting of a nicotinic component, nutraceuticals, botanicals, stimulants, amino acids, vitamins, cannabinoids, cannabamimetics, terpenes, pharmaceutical agents, and combinations thereof.
  • active ingredients selected from the group consisting of a nicotinic component, nutraceuticals, botanicals, stimulants, amino acids, vitamins, cannabinoids, cannabamimetics, terpenes, pharmaceutical agents, and combinations thereof.
  • Embodiment 31 The pouched product of Embodiment 30, wherein the composition comprises a nicotinic component selected from the group consisting of nicotine, a nicotine salt, or a resin complex of nicotine.
  • Embodiment 32 The pouched product of Embodiment 31, wherein the composition comprises a tobacco extract comprising nicotine.
  • Embodiment 33 The pouched product of any of Embodiments 1-32, wherein the composition comprises one or more components selected from the group consisting of one or more additional fillers, binders, pH adjusters, buffering agents, colorants, disintegration aids, antioxidants, humectants, and preservatives.
  • Embodiment 34 The pouched product of any of Embodiments 1-33, wherein the water content is about 15% or less by weight.
  • Embodiment 35 The pouched product of any of Embodiments 1-34, wherein the pouched product has a pH of about 7 or greater.
  • Embodiment 36 The pouched product of Embodiment 35, wherein the pouched product has a pH of about 8 to about 10.
  • Embodiment 37 The pouched product of any of Embodiments 1-36, wherein the composition comprises: a filler in an amount of about 75 to about 85% by weight; a salt in an amount of about 1 to about 3% by weight; water in an amount of about 10% by weight (e.g., about 8% to about 12% or about 9% to about 11%); and a single capsule, wherein the payload comprises menthol and the capsule wall comprises gelatin.
  • FIG. 1 is a front perspective view of a non-limiting pouched product according to an embodiment of the present disclosure
  • FIG. 2A and 2B are depictions of non-limiting capsules according to certain embodiments of the present disclosure
  • FIGs. 3A and 3B are depictures of non-limiting capsules according to certain embodiments of the present disclosure
  • FIG. 4 is a front perspective view illustrating a pouched product according to an embodiment of the present disclosure comprising a plurality of capsules;
  • FIG. 5 is a front perspective view illustrating a pouched product according to an embodiment of the present disclosure comprising a single capsule
  • FIG. 6 is a front perspective view illustrating a pouched product with a first, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule;
  • FIG. 7 is a front perspective view illustrating a pouched product with a second, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule;
  • FIG. 8 is a front perspective view illustrating a pouched product with a third, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule;
  • FIG. 9 is a front perspective view illustrating a pouched product with a fourth, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule;
  • FIG. 10 is a front perspective view illustrating a pouched product with a fifth, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule;
  • FIG. 11 is a front perspective view illustrating a pouched product with a sixth, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule;
  • FIG. 12 is a front perspective view illustrating a pouched product with a seventh, non-limiting alternative shape according to an embodiment of the present disclosure comprising a single capsule.
  • compositions and products configured for oral use generally provides compositions and products configured for oral use.
  • Configured for oral use means that the product is provided in a form such that during use, saliva in the mouth of the user causes one or more of the components of the product (e.g., flavoring agent and/or active ingredient) to pass into the mouth of the user.
  • the components of the product e.g., flavoring agent and/or active ingredient
  • the product is adapted to deliver components to a user through mucous membranes in the user's mouth, the user's digestive system, or both, and, in some instances, said component is a nicotine component or an active ingredient (including, but not limited to, for example, nicotine, a stimulant, vitamin, amino acid, botanical, or a combination thereof) that can be absorbed through the mucous membranes in the mouth or absorbed through the digestive tract when the product is used.
  • a nicotine component or an active ingredient including, but not limited to, for example, nicotine, a stimulant, vitamin, amino acid, botanical, or a combination thereof
  • the compositions and products provided herein are pouched products, e.g., in the form of a mixture of one or more components (also referred to herein as a “particulate composition”), disposed within a moisture-permeable container (e.g., a water-permeable pouch).
  • Pouched products generally comprise, in addition to the pouch-based exterior, a composition/mixture within the pouch that typically comprises one or more active ingredients and/or one or more flavorants, and various other optional ingredients. According to the present disclosure, such composition/mixture further comprises one or more objects, which includes capsules.
  • the composition/mixture can optionally include various other components; any remaining components of the composition within the pouches provided herein are not particularly limited.
  • the composition/mixture can comprise any filling composition, including those included within conventional pouched products, and further comprising one or more capsules as described herein.
  • Such particulate compositions are generally mixtures of two or more components and as such, the compositions are, in some cases, referenced herein below as “mixtures.”
  • Certain components that can advantageously be included in the mixtures within certain embodiments of the pouches provided herein are outlined generally below; however, it is to be understood that the discussion is not intended to be limiting of the components that can be incorporated within the disclosed pouches.
  • Such mixtures in the water-permeable pouch format are typically used by placing a pouch containing the mixture in the mouth of a human subject/user.
  • the pouch is placed somewhere in the oral cavity of the user, for example under the lips, in the same way as moist snuff products are generally used.
  • the pouch preferably is not chewed or swallowed. However, in some embodiments, chewing may be advantageous, e.g., to rupture the one or more capsules, where relevant.
  • Exposure to saliva causes some of the components of the mixture within the water-permeable pouch (e.g., flavoring agents and/or active agents) to pass through e.g., the water-permeable pouch and provide the user with flavor and satisfaction, and the user is not required to spit out any portion of the mixture.
  • the pouch After about 10 minutes to about 60 minutes, typically about 15 minutes to about 45 minutes, of use/enjoyment, substantial amounts of the mixture have been ingested by the human subject, and the pouch may be removed from the mouth of the consumer for disposal.
  • Preferred pouch materials for products described herein may be designed and manufactured such that under conditions of normal use, a significant amount of the contents of the formulation within the pouch permeate through the pouch material prior to the time that the pouch undergoes loss of its physical integrity.
  • an example pouched product 10 can comprise an outer water-permeable container 20 in the form of a pouch which contains a particulate mixture 15 adapted for oral use.
  • the orientation, size, and type of outer water-permeable pouch and the type and nature of the composition adapted for oral use that are illustrated herein are not construed as limiting thereof.
  • Various, non-limiting components of certain particulate mixtures 15 according to the present disclosure are described in further detail herein below.
  • Capsules 30 as provided herein generally comprise an internal payload (“filling”) component 32 and a capsule wall 34, with nonlimiting examples of such capsules depicted in FIGs. 2A and 2B.
  • FIG. 2A shows a capsule with an oval/oblong shape
  • FIG. 2B shows a capsule with a spherical shape. It is noted that these shapes are not intended to be limiting of the disclosure; the capsules 30 provided herein can have any range of shapes, such as generally rectilinear, oblong, elliptical, or oval shapes.
  • Certain capsules may have diameters of less than about 100 microns, such as microcapsules having diameters in the range of about 1 to about 40 microns, or about 1 micron to about 20 microns. In some embodiments, larger capsules may be utilized.
  • a capsule utilized in the pouch product may have a size of about 0.5 mm to about 6 mm, 0.5 to about 5 mm, or about 0.6 mm to about 3 mm in diameter.
  • Certain capsules may have diameters of about 0.5 to about 6 mm, e.g., about 1 to about 5 mm, about 1 to about 4 mm, or about 1.5 mm to about 3.5 mm, e.g., about 2 mm to about 4 mm or about 3 mm to about 4 mm.
  • the weight of the capsules can vary. In some embodiments, capsules can have a weight of about 30 mg or less, about 20 mg or less, about 10 mg or less, or about 1 mg or less. Certain specific embodiments provide capsules with individual weights of about 15 mg to about 30 mg, e.g., about 20 mg to about 25 mg.
  • the capsules may be colored, provided with smooth or rough surfaces, have rigid or pliant shells, have brittle or durable shells, or other desired features or characteristics.
  • the capsule wall 34 is generally formed of a material that is configured to allow for dispersement of the internal payload 32 under desired conditions.
  • the capsule wall may comprise a material that is configured to dissolve or otherwise degrade under mouth conditions.
  • the capsule wall 34 may comprise a material that is configured to be broken or otherwise degraded by shear forces (e.g., chewing). While suitable encapsulated materials may be described herein in relation to microcapsules, it is understood that such terminology is not intended to be viewed as limiting of the capsule sizes.
  • the crush strength of suitable capsules can be sufficient to allow for normal handling and storage without significant degree of premature or undesirable breakage.
  • the composition of the capsule wall 34 may vary depending upon the nature of the internal payload 32.
  • the capsule wall 34 can comprise, e.g., a material such as wax, gelatin, cyclodextrin, or alginate.
  • Classes of materials that can typically be used to form the capsule wall 34 include, but are not limited to, proteins, polysaccharides, starches, waxes, fats, natural and synthetic polymers, and resins.
  • Exemplary materials that can be used to form the capsule wall 34 include gelatin, acacia (gum arabic), polyvinyl acetate, potassium alginate, carob bean gum, potassium citrate, carrageenan, potassium polymetaphosphate, citric acid, potassium tripolyphosphate, dextrin, polyvinyl alcohol, povidone, dimethylpoly siloxane, dimethyl silicone, refined paraffin wax, ethylcellulose, bleached shellac, modified food starch, sodium alginate, guar gum, sodium carboxymethylcellulose, hydroxypropyl cellulose, sodium citrate, hydroxypropylmethylcellulose, sodium ferrocyanide, sodium polyphosphates, locust bean gum, methylcellulose, sodium trimetaphosphate, methyl ethyl cellulose, sodium tripolyphosphate, microcrystalline wax, tannic acid, petroleum wax, terpene resin, tragacanth, polyethylene, xanthan gum, and polyethylene glycol.
  • gelatin aca
  • Microcapsules are commercially available and can, in some embodiments, be used according to the present disclosure.
  • Certain examples of microcapsule technologies are of the type set forth in Gutcho, Microcapsules and Microencapsulation Techniques (1976); Gutcho, Microcapsules and Other Capsules Advances Since 1975 (1979); Kondo, Microcapsule Processing and Technology (1979); Iwamoto et al., AAPS Pharm. Sci. Tech. 2002 3(3): article 25; U.S. Pat. No. 3,550,598 to McGlumphy; U.S. Pat. No. 4,889,144 to Tateno et al.; U.S. Pat. No. 5,004,595 to Cherukuri et al.; U.S. Pat. No.
  • Suitable, non-limiting types of capsules are of the type commercially available as “Momints” by Yosha! Enterprises, Inc. and “Ice Breakers® Liquid Ice” from The Hershey Company. Representative types of capsules also have been incorporated in chewing gum, such as the type of gum marketed under the tradename “Cinnabursf ’ by Cadbury Adams USA. Representative types of capsules and components thereof also are set forth in U.S. Pat. No. 3,339,558 to Waterbury; U.S. Pat. No. 3,390,686 to Irby, Jr. et al.; U.S. Pat. No. 3,685,521 to Dock; U.S. Pat. No.
  • 2004/0224020 to Schoenhard 2005/0123601 to Mane et al.; 2005/0196437 to Bednarz et al.; and 2005/0249676 to Scott et al.; which are incorporated herein by reference.
  • the composition of the capsule wall 34 is selected so as to accommodate an aqueous internal payload 32 therein.
  • the composition of capsule wall 34 must be selected so as to be at least partially resistant to water, e.g., so as to retain a water-containing payload 32 therein without any substantial degradation for a period of time of about 6 months or more, about 12 months or more, about 18 months or more, or about 2 years or more at room temperature.
  • the capsule wall 34 can comprise, e.g., a starch, a functional cellulose, a cross-linked polymer, an oil/wax or any combination thereof.
  • the capsule wall 34 of a water-containing capsule can comprise a stiffer/thicker gelatin coating than conventionally used for encapsulation of particulate or non-aqueous payloads.
  • Certain nonlimiting materials that may be suitable for the capsule wall 34 of a water-containing capsule include, e.g., alginates, hydrogels, thermoplastics, biopolymers, modified starches (e.g., tapioca), shellac, sponges, or acrylates/methacrylates (for osmotic release).
  • the capsule wall 34 of a watercontaining capsule can comprise silica, e.g., such that an air-water emulsion is encapsulated by silica (referred to as “dry water”).
  • the capsule wall 34 of a water-containing capsule can comprise a membrane, e.g., as provided at oohowater.com, which is incorporated herein by reference in its entirety, comprising, e.g., sodium alginate, a natural thickener from algae and calcium chloride.
  • some capsules 30 can further comprise one or more coatings (e.g., 36a and/or 36b) on the interior and/or exterior of capsule wall 34 as shown, e.g., in FIGs. 3A and 3B.
  • a coating 36 can allow for the use of conventional capsule wall materials (e.g., such as used in capsules containing particulates or non-aqueous liquids), as the conventional capsule wall material is protected via coating 36a from enhanced degradation associated with water contact between the aqueous payload 32 and the capsule wall 34 and/or via coating 36b from enhanced degradation associated with water contact between the outer atmosphere/composition in which the capsule is included and the capsule wall 34.
  • compositions of the two coatings can be the same or different.
  • the composition of such coating(s) 36 can vary but in some embodiments, the coating can comprise a material disclosed above to be suitable for use as a capsule wall 34 for a water-containing capsule.
  • the composition of the internal payload (“filling”) component 32 can vary widely.
  • payload 32 can be comprise a particulate material, including a powder payload, a non-aqueous (e.g., organic) liquid, and/or an aqueous (i.e., water-containing) liquid.
  • Liquid-containing payloads can comprise, e.g., neat liquids, solutions, emulsions, or dispersions.
  • capsules are provided which comprise, as payload 32, an organic liquid such as an alcohol or oil.
  • capsules are provided which comprise, as payload 32, water.
  • payload 32 can comprise a mixture of water and a miscible liquid, such as alcohol or glycerin.
  • Liquid- containing payloads can comprise the liquid(s) alone or can comprise one or more additional components/additives.
  • the internal payload 32 comprises one or more release-modifying agents, e.g., as disclosed in U.S. Patent No. 11,344,057 to Chapman et al., which is incorporated herein by reference in its entirety; one or more flavorants, one or more active ingredients, or any combination of two or more thereof.
  • payload 32 comprises a flavorant (e.g., menthol). Examples of suitable additives/components that can optionally be included within payload component 32 of certain capsule embodiments are described in greater detail herein below.
  • water-containing capsules are provided, which comprise, as payload 32, at least some amount of water.
  • payload 32 consists essentially of water or consists of water.
  • the water-containing capsules 30 are designed for moisture release during use within the oral cavity.
  • payload 32 comprises water and one or more additional components, e.g., one or more flavoring agents (e.g., water-soluble flavoring agents) and/or one or more active ingredients (e.g., water-soluble active ingredients).
  • capsules 30 include, but are not limited to, a capsule comprising a menthol-containing payload 32 within a gelatin capsule wall 34.
  • the capsules 30 can be formed using any encapsulating technology known in the art.
  • microcapsules can be formed using any of various chemical encapsulation techniques such as solvent evaporation, solvent extraction, organic phase separation, interfacial polymerization, simple and complex coacervation, in-situ polymerization, liposome encapsulation, and nanoencapsulation.
  • physical methods of encapsulation could be used, such as spray coating, pan coating, fluid bed coating, annular jet coating, spinning disk atomization, spray cooling, spray drying, spray chilling, stationary nozzle coextrusion, centrifugal head coextrusion, or submerged nozzle coextrusion.
  • Coatings e.g., 36b
  • Coatings can be provided, e.g., by subjecting capsules 30 to processing within a fluid bed coater comprising the material to be coated thereon.
  • the disclosure further provides oral compositions comprising one or more of the capsules described herein.
  • the disclosure provides pouched products comprising one or more such capsules.
  • the number of capsules incorporated into a pouched product can vary, depending upon factors such as the size of the capsule(s), the character or nature of the additive in the payload, the desired attributes of the composition within the pouched product and the desired release modification thereof, and the like. In some embodiments, only a single capsule may be included within the pouched product.
  • a plurality of capsules 30, each having the same or a different payload (not visible) provided therein may be included within particulate mixture 45, positioned within an outer water-permeable container 50.
  • the plurality of capsules 30 can thus be relatively small in size.
  • microcapsules may be used.
  • the capsules may be substantially uniform or varied in size, weight, and/or shape.
  • the number of capsules incorporated within such a pouched product for example, can exceed about 5, can exceed about 10, can exceed about 20, can exceed about 40, and can even exceed about 100.
  • the number of capsules can be greater than about 500, and even greater than about 1,000.
  • the total weight of the capsules contained within such a pouched product may vary, but is typically greater than about 10 mg, often greater than about 20 mg, and can be greater than about 30 mg.
  • the total weight of the capsules is typically less than about 200 mg, often less than about 100 mg, and can be less than about 50 mg.
  • a single capsule 30 may be included within particulate mixture 65, positioned within an outer water-permeable container 70.
  • the capsule may be (although it is not required to be) larger than capsules that would otherwise be incorporated (as a plurality of capsules) within the compositions provided herein.
  • the shapes of the pouched products provided herein are not particularly limited. Non-limiting examples of additional shapes of pouched products are provided in FIGs. 6-12.
  • the edges of the illustrated pouch shapes can vary, e.g., straight, serrated, etc. Further, these figures illustrate just a single capsule 30 contained within each pouch; however, in some embodiments, the disclosure also provides pouched products of the shapes depicted in FIGs. 6-12 comprising multiple capsules.
  • compositions provided herein typically comprise one or more filler components.
  • Such particulate filler components may fulfill multiple functions, such as enhancing certain organoleptic properties such as texture and mouthfeel, enhancing cohesiveness or compressibility of the product, and the like.
  • filler components are porous, particulate materials and are cellulose-based.
  • suitable particulate filler components are any non-tobacco plant material or derivative thereof, including cellulose materials derived from such sources.
  • cellulosic non-tobacco plant material include cereal grains (e.g., maize, oat, barley, rye, buckwheat, and the like), sugar beet (e.g., FIBREX® brand filler available from International Fiber Corporation), bran fiber, and mixtures thereof.
  • Non-limiting examples of derivatives of non-tobacco plant material include starches (e.g., from potato, wheat, rice, com), natural cellulose, and modified cellulosic materials.
  • particulate filler components include maltodextrin, dextrose, calcium carbonate, calcium phosphate, lactose, mannitol, xylitol, and sorbitol. Combinations of fillers can also be used.
  • Starch as used herein may refer to pure starch from any source, modified starch, or starch derivatives. Starch is present, typically in granular form, in almost all green plants and in various types of plant tissues and organs (e.g., seeds, leaves, rhizomes, roots, tubers, shoots, fruits, grains, and stems). Starch can vary in composition, as well as in granular shape and size. Often, starch from different sources has different chemical and physical characteristics. A specific starch can be selected for inclusion in the mixture based on the ability of the starch material to impart a specific organoleptic property to composition. Starches derived from various sources can be used.
  • starch major sources include cereal grains (e.g., rice, wheat, and maize) and root vegetables (e.g., potatoes and cassava).
  • sources of starch include acorns, arrowroot, arracacha, bananas, barley, beans (e.g., favas, lentils, mung beans, peas, chickpeas), breadfruit, buckwheat, canna, chestnuts, colacasia, katakuri, kudzu, malanga, millet, oats, oca, Polynesian arrowroot, sago, sorghum, sweet potato, quinoa, rye, tapioca, taro, tobacco, water chestnuts, and yams.
  • modified starches are modified starches.
  • a modified starch has undergone one or more structural modifications, often designed to alter its high heat properties.
  • Some starches have been developed by genetic modifications, and are considered to be “genetically modified” starches.
  • Other starches are obtained and subsequently physically (e.g., heat, cool water swelling, etc.), chemically, or enzymatically modified.
  • modified starches can be starches that have been subjected to chemical reactions, such as esterification, etherification, oxidation, depolymerization (thinning) by acid catalysis or oxidation in the presence of base, bleaching, transglycosylation and depolymerization (e.g., dextrinization in the presence of a catalyst), cross-linking, acetylation, hydroxypropylation, and/or partial hydrolysis.
  • Enzymatic treatment includes subjecting native starches to enzyme isolates or concentrates, microbial enzymes, and/or enzymes native to plant materials, e.g., amylase present in com kernels to modify com starch.
  • modified starches are modified by heat treatments, such as pregelatinization, dextrinization, and/or cold water swelling processes.
  • Certain modified starches include monostarch phosphate, distarch glycerol, distarch phosphate esterified with sodium trimetaphosphate, phosphate distarch phosphate, acetylated distarch phosphate, starch acetate esterified with acetic anhydride, starch acetate esterified with vinyl acetate, acetylated distarch adipate, acetylated distarch glycerol, hydroxypropyl starch, hydroxypropyl distarch glycerol, starch sodium octenyl succinate.
  • the particulate filler component is a cellulose material or cellulose derivative and can, in some embodiments, comprise mcc.
  • the mcc may be synthetic or semi-synthetic, or it may be obtained entirely from natural celluloses.
  • the mcc may be selected from the group consisting of AVICEL® grades PH-100, PH-102, PH-103, PH-105, PH-112, PH-113, PH-200, PH-300, PH-302, VIVACEL® grades 101, 102, 12, 20 and EMOCEL® grades 50M and 90M, and the like, and mixtures thereof.
  • the composition comprises mcc as the particulate filler; the quantity of mcc present may vary according to the desired properties.
  • the amount of filler can vary, but is typically up to about 90 percent of the particulate composition by weight, based on the total weight of the composition.
  • a typical range of filler (e.g., mcc) within the composition can be from about 10 to about 85% by total weight of the composition, for example, from about 10, about 15, about 20, about 25, or about 30 to about 45, about 50, about 65, or about 75 weight percent (e.g., about 20 to about 80 weight percent or about 25 to about 75 weight percent).
  • the amount of filler is at least about 10 percent by weight, such at least about 20 percent, at least about 30 percent, at least about 40 percent, or at least about 50%, based on the total weight of the composition.
  • the filler further comprises a cellulose derivative or a combination of such derivatives.
  • the mixture comprises from about l% to about 10% of the cellulose derivative by weight, based on the total weight of the composition, with certain embodiments comprising about 1 to about 5% by weight of cellulose derivative.
  • the cellulose derivative is a cellulose ether (including carboxyalkyl ethers), meaning a cellulose polymer with the hydrogen of one or more hydroxyl groups in the cellulose structure replaced with an alkyl, hydroxyalkyl, or aryl group.
  • Non-limiting examples of such cellulose derivatives include methylcellulose, hydroxypropylcellulose ("HPC”), hydroxypropylmethylcellulose (“HPMC”), hydroxyethyl cellulose, and carboxymethylcellulose (“CMC”).
  • the cellulose derivative is one or more of methylcellulose, HPC, HPMC, hydroxyethyl cellulose, and CMC.
  • the cellulose derivative is HPC.
  • the mixture comprises from about 0% to about 5% HPC by weight, e.g., about 1% to about 3% HPC by weight, based on the total weight of the mixture.
  • the composition comprises, as a fdler, a byproduct of a pulping process, such as citrus rinds.
  • the composition comprises, as a fdler, wheat straw.
  • fdlers can be used in combination with any of the types of particulate fdlers referenced herein above.
  • the water content and oven volatiles of the composition within the pouched product described herein, prior to use by a consumer of the product may vary according to the desired properties.
  • the mixture, as present within the product prior to insertion into the mouth of the user is less than about 60 percent by weight of water, and generally is from about 1 to about 60% by weight of water, for example, from about 5 to about 55, about 10 to about 50, about 20 to about 45, or about 25 to about 40 percent water by weight, including water amounts of at least about 5% by weight, at least about 10% by weight, at least about 15% by weight, and at least about 20% by weight.
  • the water content of the particulate composition is considered low, e.g., about 1% to about 12% by weight, such as less than about 10%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, or less than about 4% by weight, based on the total weight of the particulate composition.
  • Flavoring agent e.g., about 1% to about 12% by weight, such as less than about 10%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, or less than about 4% by weight, based on the total weight of the particulate composition.
  • the composition comprises one or more flavoring agents.
  • the particulate composition comprises one or more capsules 30 wherein the payload 32 comprises one or more flavoring agents.
  • the one or more flavoring agents within the capsule(s) 30 are the only flavoring agents within the particulate composition.
  • the particulate composition further comprises one or more additional flavorants (wherein the one or more additional flavorants (in non-encapsulated form) can be the same as or different than the one or more flavorants within payload 32 of the capsule(s)).
  • the capsule(s) 30 within a given particulate composition do not comprise a flavorant; in such embodiments, the particulate composition typically comprises one or more non-encapsulated flavorants.
  • the flavoring agents described herein below are relevant in both encapsulated and non-encapsulated forms.
  • flavoring agent or “flavorant” is any flavorful or aromatic substance capable of altering the sensory characteristics associated with the oral product.
  • sensory characteristics that can be modified by the flavoring agent include taste, mouthfeel, moistness, coolness/heat, and/or fragrance/aroma.
  • Flavoring agents may be or synthetic, and the character of the flavors imparted thereby may be described, without limitation, as fresh, sweet, herbal, confectionary, floral, fruity, or spicy.
  • Flavoring agents may be imitation, synthetic, or natural ingredients or blends thereof. Flavoring agents may include naturally occurring flavor materials, botanicals, extracts of botanicals, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice (liquorice), hydrangea, Japanese white bark magnolia leaf, chamomile, fenugreek, maple, matcha, Japanese mint, aniseed (anise), turmeric, Indian spices, Asian spices, herb, wintergreen, cherry, berry, red berry, cranberry, peach, apple, orange, mango, clementine, lemon, lime, tropical fruit, papaya, rhubarb, grape, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch, whiskey, gin, tequila, rum, spearmint, peppermint, lavender, aloe vera, cardamom, celery, cascarilla, nutmeg, sandalwood,
  • flavors include, but are not limited to, vanilla, coffee, chocolate/cocoa, cream, mint, spearmint, menthol, peppermint, wintergreen, eucalyptus, lavender, cardamon, nutmeg, cinnamon, clove, cascarilla, sandalwood, honey, jasmine, ginger, anise, sage, licorice, lemon, orange, apple, peach, lime, cherry, strawberry, trigeminal sensates, melatonin, terpenes, and any combinations thereof. See also, Leffmgwell et al., Tobacco Flavoring for Smoking Products, R. J. Reynolds Tobacco Company (1972), which is incorporated herein by reference.
  • Flavorings also may include components that are considered moistening, cooling or smoothening agents, such as eucalyptus or menthol. These flavors may be provided neat (i.e., alone) or in a composite, and may be employed as concentrates or flavor packages (e.g., spearmint and menthol, orange and cinnamon; lime, pineapple, and the like). Representative types of components also are set forth in US Pat. No. 5,387,416 to White et al.; US Pat. App. Pub. No. 2005/0244521 to Strickland et al.; and PCT Application Pub. No. WO 05/041699 to Quinter et al., each of which is incorporated herein by reference. In some instances, the flavoring agent may be provided in a spray-dried form or a liquid form.
  • the flavoring agent generally comprises at least one volatile flavor component.
  • volatile refers to a chemical substance that forms a vapor readily at ambient temperatures (i.e., a chemical substance that has a high vapor pressure at a given temperature relative to a nonvolatile substance).
  • a volatile flavor component has a molecular weight below about 400 Da, and often include at least one carbon-carbon double bond, carbon-oxygen double bond, or both.
  • the at least one volatile flavor component comprises one or more alcohols, aldehydes, aromatic hydrocarbons, ketones, esters, terpenes, terpenoids, or a combination thereof.
  • Non-limiting examples of aldehydes include vanillin, ethyl vanillin, p-anisaldehyde, hexanal, furfural, isovaleraldehyde, cuminaldehyde, benzaldehyde, and citronellal.
  • Non-limiting examples of ketones include 1 -hydroxy-2 -propanone and 2-hydroxy-3-methyl-2-cyclopentenone-l-one.
  • Non-limiting examples of esters include allyl hexanoate, ethyl heptanoate, ethyl hexanoate, isoamyl acetate, and 3- methylbutyl acetate.
  • Non-limiting examples of terpenes include sabinene, limonene, gamma-terpinene, beta-famesene, nerolidol, thujone, myrcene, geraniol, nerol, citronellol, linalool, and eucalyptol.
  • the at least one volatile flavor component comprises one or more of ethyl vanillin, cinnamaldehyde, sabinene, limonene, gamma-terpinene, beta-famesene, or citral.
  • the at least one volatile flavor component comprises ethyl vanillin.
  • the at least one volatile flavor component comprises menthol.
  • the flavoring agent may be provided in a spray-dried form or a liquid form.
  • a liquid flavorant is disposed (i.e., adsorbed or absorbed in or on) a porous particulate carrier, for example microcrystalline cellulose, which is then combined with the other composition ingredients.
  • a porous particulate carrier for example microcrystalline cellulose
  • Embodiments with flavorant present in dry form may be advantageous in providing a more homogenous product.
  • the amount of flavoring agent, where present in the mixture/composition (in capsule and/or unencapsulated forms) can vary, but is typically up to about 10 weight percent, and certain embodiments are characterized by a flavoring agent content of at least about 0. 1 weight percent, such as about 0.1 to about 1 weight percent, 0.5 to about 10 weight percent, about 1 to about 6 weight percent, or about 2 to about 5 weight percent, based on the total weight of the particulate composition/mixture.
  • the amount of flavoring agent present within the mixture may vary over a period of time (e.g., during a period of storage after preparation of the mixture). For example, certain volatile components present in the mixture may evaporate or undergo chemical transformations, leading to a reduction in the concentration of one or more volatile flavor components.
  • the composition may include one or more taste modifying agents ("taste modifiers") which may serve to mask, alter, block, or improve e.g., the flavor of a composition as described herein.
  • taste modifiers include analgesic or anesthetic herbs, spices, and flavors which produce a perceived cooling (e.g., menthol, eucalyptus, mint), warming (e.g., cinnamon), or painful (e.g., capsaicin) sensation.
  • Certain taste modifiers fall into more than one overlapping category.
  • the taste modifier modifies one or more of bitter, sweet, salty, or sour tastes.
  • the taste modifier targets pain receptors.
  • the composition comprises an active ingredient having a bitter taste, and a taste modifier which masks or blocks the perception of the bitter taste.
  • the taste modifier is a substance which targets pain receptors (e.g., vanilloid receptors) in the user's mouth to mask e.g., a bitter taste of another component (e.g., an active ingredient).
  • the taste modifier is capsaicin.
  • the taste modifier is the amino acid gamma-amino butyric acid (GABA), referenced herein above with respect to amino acids.
  • GABA amino acid gamma-amino butyric acid
  • the composition comprises caffeine and GABA.
  • the taste modifier is adenosine monophosphate (AMP).
  • AMP is a naturally occurring nucleotide substance which can block bitter food flavors or enhance sweetness. It does not directly alter the bitter flavor, but may alter human perception of "bitter” by blocking the associated receptor.
  • the taste modifier is lactisole. Lactisole is an antagonist of sweet taste receptors. Temporarily blocking sweetness receptors may accentuate e.g., savory notes.
  • the taste modifier is adenosine monophosphate (AMP).
  • a representative amount of taste modifier is about 0.01% by weight or more, about 0.1% by weight or more, or about 1.0% by weight or more, but will typically make up less than about 10% by weight of the total weight of the composition, (e.g., from about 0.01%, about 0.05%, about 0.1%, or about 0.5%, to about 1%, about 5%, or about 10% by weight of the total weight of the composition).
  • the mixture may further comprise a salt (e.g., alkali metal salts), typically employed in an amount sufficient to provide desired sensory attributes to the mixture.
  • a salt e.g., alkali metal salts
  • suitable salts include sodium chloride, potassium chloride, ammonium chloride, flour salt, and the like.
  • a representative amount of salt is about 0.5 percent by weight or more, about 1.0 percent by weight or more, or at about 1.5 percent by weight or more, but will typically make up about 10 percent or less of the total weight of the mixture, or about 7.5 percent or less or about 5 percent or less (e.g., about 0.5 to about 5 percent by weight).
  • the mixture typically further comprises one or more sweeteners.
  • the sweeteners can be any sweetener or combination of sweeteners, in natural or artificial form, or as a combination of natural and artificial sweeteners.
  • natural sweeteners include isomaltulose, fructose, sucrose, glucose, maltose, mannose, galactose, lactose, stevia, honey, and the like.
  • artificial sweeteners include sucralose, maltodextrin, saccharin, aspartame, acesulfame K, neotame and the like.
  • the sweetener comprises one or more sugar alcohols.
  • Sugar alcohols are polyols derived from monosaccharides or disaccharides that have a partially or fully hydrogenated form.
  • Sugar alcohols have, for example, about 4 to about 20 carbon atoms and include erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof (e.g., hydrogenated starch hydrolysates).
  • the sweetener is sucralose, acesulfame K, or a combination thereof.
  • the mixture provided herein can include a sugar alcohol (e.g., xylitol or erythritol) in combination with a lesser amount of artificial sweetener (e.g., sucralose, aspartame, acesulfame K, or any combination thereof).
  • a representative amount of sweetener may make up from about 0.01 to about 20 percent or more of the of the mixture by weight, for example, from about 0. 1 to about 1%, from about 1 to about 5%, from about 5 to about 10%, or from about 10 to about 20% of the mixture on a weight basis, based on the total weight of the mixture.
  • a binding agent/binder may be employed in certain embodiments, in amounts sufficient to provide the desired physical attributes and physical integrity to the mixture. Binders also often function as thickening or gelling agents. Typical binders can be organic or inorganic, or a combination thereof. Representative binders include modified cellulose, povidone, sodium alginate, starch-based binders, pectin, carrageenan, pullulan, zein, and the like, and combinations thereof. In some embodiments, the binder comprises pectin or carrageenan or combinations thereof.
  • a binder may be employed in amounts sufficient to provide the desired physical attributes and physical integrity to the mixture.
  • the amount of binder utilized in the mixture can vary, but is typically up to about 30 weight percent, and certain embodiments are characterized by a binder content of at least about 0. 1% by weight, such as about 1 to about 30% by weight, or about 5 to about 10% by weight, based on the total weight of the mixture.
  • the composition/mixture provided herein is free of (i.e., does not contain) any binder component, e.g., gum.
  • the binder includes a gum, for example, a natural gum.
  • a natural gum refers to polysaccharide materials of natural origin that have binding properties, and which are also useful as a thickening or gelling agents.
  • Representative natural gums derived from plants, which are typically water soluble to some degree, include xanthan gum, guar gum, gum arabic, ghatti gum, gum tragacanth, karaya gum, locust bean gum, gellan gum, and combinations thereof.
  • natural gum binder materials are typically present in an amount of up to about 5% by weight, for example, from about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about 1%, to about 2, about 3, about 4, or about 5% by weight, based on the total weight of the mixture.
  • one or more humectants may be employed in the mixture.
  • humectants include, but are not limited to, polyols such as glycerin, propylene glycol, and the like.
  • the humectant is typically provided in an amount sufficient to provide desired moisture attributes to the mixture.
  • the humectant may impart desirable flow characteristics to the mixture for depositing in a mold.
  • a humectant will typically make up about 10% or less of the weight of the mixture or 5% or less of the weight of the mixture (e.g., from about 2% to about 10% by weight or about 0.5% to about 5% by weight).
  • a representative amount of humectant is about 0.1% to about 1% by weight, about 0. 1% to about 0.5% by weight, or about 1% to about 5% by weight, based on the total weight of the mixture.
  • a flow aid can also be added to the composition in order to enhance flowability of the composition.
  • the composition e.g., melt and chew forms
  • Exemplary flow aids include microcrystalline cellulose, silica, polyethylene glycol, stearic acid, calcium stearate, magnesium stearate, zinc stearate, sodium stearyl fumarate, canauba wax, and combinations thereof.
  • the flow aid is sodium stearyl fumarate.
  • a representative amount of flow aid may make up at least about 0.5 percent or at least about 1 percent, of the total dry weight of the composition.
  • the amount of flow aid within the composition will not exceed about 5 percent, and frequently will not exceed about 3 percent, of the total dry weight of the mixture/composition.
  • the mixture of the present disclosure can comprise pH adjusters or buffering agents.
  • pH adjusters and buffering agents that can be used include, but are not limited to, metal hydroxides (e.g., alkali metal hydroxides such as sodium hydroxide and potassium hydroxide), and other alkali metal buffers such as metal carbonates (e.g., potassium carbonate or sodium carbonate), or metal bicarbonates such as sodium bicarbonate, and the like.
  • the buffering agent is typically present in an amount less than about 5 percent based on the weight of the mixture, for example, from about 0.
  • Suitable buffers include alkali metals acetates, glycinates, phosphates, glycerophosphates, citrates, carbonates, hydrogen carbonates, borates, or mixtures thereof.
  • Oral care ingredient include alkali metals acetates, glycinates, phosphates, glycerophosphates, citrates, carbonates, hydrogen carbonates, borates, or mixtures thereof.
  • the mixture comprises an oral care ingredient (or a mixture of such ingredients).
  • Oral care ingredients provide the ability to inhibit tooth decay or loss, inhibit gum disease, relieve mouth pain, whiten teeth, or otherwise inhibit tooth staining, elicit salivary stimulation, inhibit breath malodor, freshen breath, or the like.
  • effective amounts of ingredients such as thyme oil, eucalyptus oil and zinc (e.g., such as the ingredients of formulations commercially available as ZYTEX® from Discus Dental) can be incorporated into the composition.
  • ingredients that can be incorporated in desired effective amounts within the present composition can include those that are incorporated within the types of oral care compositions set forth in Takahashi et al., Oral Microbiology and Immunology, 19(1), 61-64 (2004); U.S. Pat. No. 6,083,527 to Thistle; and US Pat. Appl. Pub. Nos. 2006/0210488 to Jakubowski and 2006/02228308 to Cummins et al.
  • Other exemplary ingredients of tobacco containing-formulation include those contained in formulations marketed as MALTISORB® by Roquette and DENTIZYME® by NatraRx.
  • a representative amount of oral care additive is at least about 1%, often at least about 3%, and frequently at least about 5% of the total dry weight of the composition.
  • the amount of oral care additive within the composition will not typically exceed about 30%, often will not exceed about 25%, and frequently will not exceed about 20%, of the total dry weight of the mixture/composition.
  • Colorant A colorant may optionally be employed in amounts sufficient to provide the desired physical attributes to the mixture.
  • Natural or synthetic colorants such as natural or synthetic dyes, food-grade colorants and pharmaceutical-grade colorants may be used. Examples of colorants include various dyes and pigments, such as caramel coloring and titanium dioxide. Natural colorants such as curcumin, beet juice extract, spirulina can be used; a variety of synthetic pigments may also be used.
  • the amount of colorant utilized in the mixture can vary, but when present is typically up to about 3 weight percent, such as from about 0.1%, about 0.5%, or about 1%, to about 3% by weight, based on the total weight of the mixture.
  • the particulate composition comprises one or more active ingredients.
  • the particulate composition comprises one or more capsules 30 wherein the payload 32 comprises one or more active ingredients.
  • the one or more active ingredients within the capsule(s) 30 are the only active ingredients within the particulate composition.
  • the particulate composition further comprises one or more additional active ingredients (wherein the one or more additional active ingredients (in non-encapsulated form) can be the same as or different than the one or more active ingredients within payload 32 of the capsule(s)).
  • the capsule(s) 30 within a given particulate composition do not comprise an active ingredient; in such embodiments, the particulate composition typically comprises one or more nonencapsulated active ingredients.
  • the active ingredients described herein below are relevant in both encapsulated and non-encapsulated forms.
  • an "active ingredient” refers to one or more substances belonging to any of the following categories: API (active pharmaceutical ingredient), food additives, natural medicaments, and naturally occurring substances that can have an effect on humans.
  • Example active ingredients include any ingredient known to impact one or more biological functions within the body, such as ingredients that furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or which affect the structure or any function of the body of humans (e.g., provide a stimulating action on the central nervous system, have an energizing effect, an antipyretic or analgesic action, or an otherwise useful effect on the body).
  • the active ingredient may be of the type generally referred to as dietary supplements, nutraceuticals, "phytochemicals” or “functional foods.”
  • dietary supplements e.g., nutraceuticals, "phytochemicals” or “functional foods.”
  • Non-limiting examples of active ingredients include those falling in the categories of botanical ingredients, stimulants, amino acids, nicotine components, and/or pharmaceutical, nutraceutical, and medicinal ingredients (e.g., vitamins, such as A, B3, B6, B12, and C, and/or cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD)). Each of these categories is further described herein below.
  • the particular choice of active ingredients will vary depending upon the desired flavor, texture, and desired characteristics of the particular product.
  • the active ingredient is selected from the group consisting of caffeine, taurine, GABA, theanine, vitamin C, lemon balm extract, ginseng, citicoline, sunflower lecithin, and combinations thereof.
  • the active ingredient can include a combination of caffeine, theanine, and optionally ginseng.
  • the active ingredient includes a combination of theanine, gamma-amino butyric acid (GABA), and lemon balm extract.
  • the active ingredient includes theanine, theanine and tryptophan, or theanine and one or more B vitamins (e.g., vitamin B6 or B12).
  • the active ingredient includes a combination of caffeine, taurine, and vitamin C.
  • an active ingredient or combination thereof is present in a total concentration of at least about 0.001% by weight of the composition, such as in a range from about 0.001% to about 30% or about 0.001% to about 20%.
  • the active ingredient or combination of active ingredients is present in a concentration from about 0.1% by weight to about 10%, about 20%, or about 30% by weight, such as, e.g., from about 0.5% by weight to about 30%, from about 0.5% by weight to about 20%, from about 0.5% by weight to about 10%, from about 1% by weight to about 10%, or from about 1% by weight to about 5% by weight, based on the total weight of the composition.
  • the active ingredient or combination of active ingredients is present in a concentration of from about 0.001%, about 0.01%, about 0.1%, or about 1%, up to about 20% by weight, such as, e.g., from about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about
  • the active ingredient comprises a botanical ingredient.
  • botanical ingredient refers to any plant material or fungal-derived material, including plant material in its natural form and plant material derived from natural plant materials, such as extracts or isolates from plant materials or treated plant materials (e.g., plant materials subjected to heat treatment, fermentation, bleaching, or other treatment processes capable of altering the physical and/or chemical nature of the material).
  • a “botanical” includes, but is not limited to, "herbal materials,” which refer to seed-producing plants that do not develop persistent woody tissue and are often valued for their medicinal or sensory characteristics (e.g., teas or tisanes).
  • compositions as disclosed herein can be characterized as free of any tobacco material (e.g., any embodiment as disclosed herein may be completely or substantially free of any tobacco material).
  • substantially free is meant that no tobacco material has been intentionally added.
  • certain embodiments can be characterized as having less than 0.001% by weight of tobacco, or less than 0.0001%, or even 0% by weight of tobacco.
  • a botanical When present, a botanical is typically at a concentration of from about 0.01% w/w to about 10% by weight, such as, e.g., from about 0.01% w/w, about 0.05%, about 0.1%, or about 0.5%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight, based on the total weight of the composition.
  • the botanical materials useful in the present disclosure may comprise, without limitation, any of the compounds and sources set forth herein, including mixtures thereof. Certain botanical materials of this type are sometimes referred to as dietary supplements, nutraceuticals, "phytochemicals” or “functional foods.” Certain botanicals, as the plant material or an extract thereof, have found use in traditional herbal medicine, and are described further herein.
  • Non-limiting examples of non-tobacco botanical materials include, without limitation, acai berry (Euterpe oleraceci martins)' , acerola (Malpighia glabra), alfalfa, allspice, Angelica root, anise (e.g., star anise), annatto seed, apple (Mains domestica), apricot oil, ashwagandha, Bacopa monniera, baobab, basil (Ocimum basilicum), bay, bee balm, beet root, bergamot, blackberry (Morns nigra), black cohosh, black pepper, black tea, blueberries, boldo (Peumus boldus), borage, bugleweed, cacao, calamus root, camu (Myrcaria dubia), cannabis/hemp, caraway seed, cardamom, cassis, catnip, catuaba, cayenne pepper, Centella asiatica, chaga mushroom, Chai
  • the active ingredient comprises lemon balm.
  • Lemon balm (Melissa officinalis) is a mildly lemon-scented herb from the same family as mint (Lamiaceae). The herb is native to Europe, North Africa, and West Asia. The tea of lemon balm, as well as the essential oil and the extract, are used in traditional and alternative medicine.
  • the active ingredient comprises lemon balm extract.
  • the lemon balm extract is present in an amount of from about 1 to about 4% by weight, based on the total weight of the composition.
  • the active ingredient comprises ginseng.
  • Ginseng is the root of plants of the genus Panax, which are characterized by the presence of unique steroid saponin phytochemicals (ginsenosides) and gintonin. Ginseng finds use as a dietary supplement in energy drinks or herbal teas, and in traditional medicine. Cultivated species include Korean ginseng (P. ginseng), South China ginseng (P. notoginseng), and American ginseng (P. quinquefolius). American ginseng and Korean ginseng vary in the type and quantity of various ginsenosides present. In some embodiments, the ginseng is American ginseng or Korean ginseng. In specific embodiments, the active ingredient comprises Korean ginseng. In some embodiments, ginseng is present in an amount of from about 0.4 to about 0.6% by weight, based on the total weight of the composition.
  • the active ingredient comprises one or more stimulants.
  • stimulants refers to a material that increases activity of the central nervous system and/or the body, for example, enhancing focus, cognition, vigor, mood, alertness, and the like.
  • Non-limiting examples of stimulants include caffeine, theacrine, theobromine, and theophylline.
  • Theacrine (1,3,7,9- tetramethyluric acid) is a purine alkaloid which is structurally related to caffeine, and possesses stimulant, analgesic, and anti-inflammatory effects.
  • Present stimulants may be natural, naturally derived, or wholly synthetic.
  • certain botanical materials may possess a stimulant effect by virtue of the presence of e.g., caffeine or related alkaloids, and accordingly are “natural” stimulants.
  • the stimulant e.g., caffeine, theacrine
  • caffeine can be obtained by extraction and purification from botanical sources (e.g., tea).
  • whole synthetic it is meant that the stimulant has been obtained by chemical synthesis.
  • the active ingredient comprises caffeine.
  • the caffeine is present in an encapsulated form. On example of an encapsulated caffeine is Vitashure®, available from Balchem Corp., 52 Sunrise Park Road, New Hampton, NY, 10958.
  • a stimulant or combination of stimulants is typically at a concentration of from about 0.1% w/w to about 15% by weight, such as, e.g., from about 0.1% w/w, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight, based on the total weight of the composition.
  • the composition comprises caffeine in an amount of from about 1.5 to about 6% by weight, based on the total weight of the composition;
  • the active ingredient comprises an amino acid.
  • amino acid refers to an organic compound that contains amine (-NH2) and carboxyl (-COOH) or sulfonic acid (SO3H) functional groups, along with a side chain (R group), which is specific to each amino acid.
  • Amino acids may be proteinogenic or non-proteinogenic. By “proteinogenic” is meant that the amino acid is one of the twenty naturally occurring amino acids found in proteins.
  • the proteinogenic amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
  • non-proteinogenic is meant that either the amino acid is not found naturally in protein, or is not directly produced by cellular machinery (e.g., is the product of post- translational modification).
  • Non-limiting examples of non-proteinogenic amino acids include gamma- aminobutyric acid (GABA), taurine (2-aminoethanesulfonic acid), theanine (L-y-glutamylethylamide), hydroxyproline, and beta-alanine.
  • the active ingredient comprises theanine.
  • the active ingredient comprises GABA.
  • the active ingredient comprises a combination of theanine and GABA.
  • the active ingredient is a combination of theanine, GABA, and lemon balm.
  • the active ingredient is a combination of caffeine, theanine, and ginseng.
  • the active ingredient comprises taurine.
  • the active ingredient is a combination of caffeine and taurine.
  • an amino acid or combination of amino acids is typically at a concentration of from about 0.1% w/w to about 15% by weight, such as, e.g., from about 0.1% w/w, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight, based on the total weight of the composition.
  • the active ingredient comprises a vitamin or combination of vitamins.
  • vitamin refers to an organic molecule (or related set of molecules) that is an essential micronutrient needed for the proper functioning of metabolism in a mammal.
  • vitamins required by human metabolism are: vitamin A (as all -trans-retinol, all-trans-retinyl- esters, as well as all -trans-beta-carotene and other provitamin A carotenoids), vitamin Bl (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B7 (biotin), vitamin B9 (folic acid or folate), vitamin B12 (cobalamins), vitamin C (ascorbic acid), vitamin D (calciferols), vitamin E (tocopherols and tocotrienols), and vitamin K (quinones).
  • the active ingredient comprises vitamin C. In some embodiments, the active ingredient is a combination of vitamin C, caffeine, and taurine. In some embodiments, the active ingredient comprises one or more of vitamin B6 and B12. In some embodiments, the active ingredient comprises theanine and one or more of vitamin B6 and B12.
  • a vitamin or combination of vitamins is typically at a concentration of from about 0.01% w/w to about 6% by weight, such as, e.g., from about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 0.1% w/w, to about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5% , or about 6% by weight, based on the total weight of the composition.
  • the active ingredient comprises vitamin A.
  • the vitamin A is encapsulated.
  • the vitamin is vitamin B6, vitamin B12, vitamin E, vitamin C, or a combination thereof.
  • the active ingredient comprises a mineral.
  • mineral refers to an inorganic molecule (or related set of molecules) that is an essential micronutrient needed for the proper functioning of various systems in a mammal.
  • minerals include iron, zinc, copper, selenium, chromium, cobalt, manganese, calcium, phosphorus, sulfur, magnesium, and the like.
  • the active ingredient comprises iron. Suitable sources of iron include, but are not limited to, ferrous salts such as ferrous sulfate and ferrous gluconate. In some embodiments, the iron is encapsulated.
  • the active ingredient comprises one or more antioxidants.
  • antioxidant refers to a substance which prevents or suppresses oxidation by terminating free radical reactions, and may delay or prevent some types of cellular damage. Antioxidants may be naturally occurring or synthetic. Naturally occurring antioxidants include those found in foods and botanical materials. Non-limiting examples of antioxidants include certain botanical materials, vitamins, polyphenols, and phenol derivatives.
  • Examples of botanical materials which are associated with antioxidant characteristics include without limitation acai berry, alfalfa, allspice, annatto seed, apricot oil, basil, bee balm, wild bergamot, black pepper, blueberries, borage seed oil, bugleweed, cacao, calamus root, catnip, catuaba, cayenne pepper, chaga mushroom, chervil, cinnamon, dark chocolate, potato peel, grape seed, ginseng, gingko biloba, Saint John's Wort, saw palmetto, green tea, black tea, black cohosh, cayenne, chamomile, cloves, cocoa powder, cranberry, dandelion, grapefruit, honeybush, echinacea, garlic, evening primrose, feverfew, ginger, goldenseal, hawthorn, hibiscus flower, jiaogulan, kava, lavender, licorice, marjoram, milk thistle, mints (menthe), oo
  • Such botanical materials may be provided in fresh or dry form, essential oils, or may be in the form of an extracts.
  • the botanical materials (as well as their extracts) often include compounds from various classes known to provide antioxidant effects, such as minerals, vitamins, isoflavones, phytoesterols, allyl sulfides, dithiolthiones, isothiocyanates, indoles, lignans, flavonoids, polyphenols, and carotenoids.
  • Examples of compounds found in botanical extracts or oils include ascorbic acid, peanut endocarb, resveratrol, sulforaphane, beta-carotene, lycopene, lutein, co-enzyme Q, carnitine, quercetin, kaempferol, and the like. See, e.g., Santhosh et al., Phytomedicine, 12(2005) 216-220, which is incorporated herein by reference.
  • Non-limiting examples of other suitable antioxidants include citric acid, Vitamin E or a derivative thereof, a tocopherol, epicatechol, epigallocatechol, epigallocatechol gallate, erythorbic acid, sodium erythorbate, 4-hexylresorcinol, theaflavin, theaflavin monogallate A or B, theaflavin digallate, phenolic acids, glycosides, quercitrin, isoquercitrin, hyperoside, polyphenols, catechols, resveratrols, oleuropein, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tertiary butylhydroquinone (TBHQ), and combinations thereof.
  • a tocopherol epicatechol, epigallocatechol, epigallocatechol gallate
  • erythorbic acid sodium erythorbate
  • 4-hexylresorcinol theaf
  • an antioxidant is typically at a concentration of from about 0.001% w/w to about 10% by weight, such as, e.g., from about 0.001%, about 0.005%, about 0.01% w/w, about 0.05%, about 0.1%, or about 0.5%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%, based on the total weight of the mixture/composition.
  • the pouched products of the present disclosure can include a nicotinic compound.
  • nicotinic compound or “source of nicotine” often refers to naturally-occurring or synthetic nicotinic compound unbound from a plant material, meaning the compound is at least partially purified and not contained within a plant structure, such as a tobacco leaf.
  • Nicotine may be tobacco-derived (e.g., a tobacco extract) or non-tobacco-derived (e.g., synthetic or otherwise obtained). Most preferably, nicotine is naturally-occurring and obtained as an extract from a. Nicotiana species (e.g., tobacco).
  • the nicotine can be, for example, in the form of a highly purified tobacco extract.
  • Various methods are known for the isolation and purification of nicotine from tobacco (including, but not limited to, extraction from tobacco with water; extraction from tobacco with organic solvents; steam distillation from tobacco; or pyrolytic degradation of tobacco and distillation of nicotine therefrom).
  • extraction methods see for example, U.S. Patent Nos. 2,822,306 and 4,153,063 to Roselius et al. and US Pat. App. Pub. No. 2008/0302377 to Kauryzbaev et al., which are incorporated herein by reference.
  • nicotine may be obtained from another source (e.g., another type of plant).
  • nicotine may be synthetically made.
  • the method by which synthetic nicotine used in some embodiments of the compositions and products described herein is synthesized can vary and is not particularly limited.
  • Various methods for the preparation of nicotine are known. See, e.g., Florence L. Wagner et al., 63 Tetrahedron 8065 (2007); U.S. Patent No. 10,913,962 to McCague et al.; and U.S. Patent App. Pub. No. 2020/0331884 to Weber et al., which are incorporated herein by reference in their entireties.
  • the nicotine can have the enantiomeric form S(-)-nicotine, R(+)-nicotine, or a mixture of S(-)- nicotine and R(+) -nicotine.
  • the nicotine is in the form of S(-)-nicotine (e.g., in a form that is virtually all S(-)-nicotine) or a racemic mixture composed primarily or predominantly of S(-)- nicotine (e.g., a mixture composed of about 95 weight parts S(-)-nicotine and about 5 weight parts R(+)- nicotine).
  • the nicotine is employed in virtually pure form or in an essentially pure form. Highly preferred nicotine that is employed has a purity of greater than about 95 percent, more preferably greater than about 98 percent, and most preferably greater than about 99 percent, on a weight basis.
  • a nicotine component may be included in the mixture in free base form, salt form, as a complex, or as a solvate.
  • nicotine component is meant any suitable form of nicotine (e.g., free base or salt) for providing oral absorption of at least a portion of the nicotine present.
  • the nicotine component is selected from the group consisting of nicotine free base, nicotine as an ion pair, and a nicotine salt.
  • at least a portion of the nicotine is in its free base form.
  • at least a portion of the nicotine is present as a nicotine salt, or present as an ion pair with at least a portion of the organic acid or the conjugate base thereof, as described further herein below.
  • Nicotine is in its free base form, can, in some embodiments, be adsorbed in for example, a microcrystalline cellulose material to form a microcrystalline cellulose-nicotine carrier complex. See, for example, the discussion of nicotine in free base form in US Pat. Pub. No. 2004/0191322 to Hansson, which is incorporated herein by reference.
  • the nicotine can be employed in the form of a salt.
  • Salts of nicotine can be provided using the types of ingredients and techniques set forth in US Pat. No. 2,033,909 to Cox et al. and Perfetti, Beitrage Tabak Kauutz. Int., 12: 43-54 (1983), which are incorporated herein by reference. Additionally, salts of nicotine are available from sources such as Pfaltz and Bauer, Inc. and K&K Uaboratories, Division of ICN Biochemicals, Inc.
  • the nicotine component is selected from the group consisting of nicotine free base, a nicotine salt such as hydrochloride, dihydrochloride, monodentate, bitartrate, sulfate, salicylate, and nicotine zinc chloride.
  • the nicotine component or a portion thereof is a nicotine salt with one or more organic acids.
  • the nicotine component is a nicotine-polymer complex.
  • Such complexes comprise a polymeric resin (e.g., a polymeric ion-exchange resin, e.g., a polymeric cation exchange resin) to which nicotine is bound.
  • a polymeric resin e.g., a polymeric ion-exchange resin, e.g., a polymeric cation exchange resin
  • a polymethacrilic acid such as Amberlite IRP64, Purolite Cl 15HMR, or Doshion P551. See, for example, US Pat. No. 3,901,248 to Uichtneckert et al., which is incorporated herein by reference.
  • Another example is a nicotine -polyacrylic carbomer complex, such as Carbopol 974P.
  • nicotine may be present in the form of a nicotine polyacrylic complex.
  • a suitable nicotine-polymer complex is nicotine polacrilex, which comprises nicotine bound to a resin prepared from methacrylic acid and divinyl benzene. Nicotine polacrilex is available in varying nicotine percentages, e.g., 18% to 20% nicotine; although not limited thereto, nicotine polacrilex generally comprises not less than 95% of the labeled amount of nicotine, calculated on an anhydrous basis.
  • inclusion of a nicotine component in the form of a nicotine-polymer complex can lead to improved shelf-life stability and slower release of the nicotine. In some embodiments, inclusion of a nicotine component in the form of a nicotine-polymer complex can lead to less bum in the oral cavity or throat during use.
  • the amount of nicotine provided by the nicotine-polymer complex can vary from about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, or about 60% to about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or 100%, based on the total weight of nicotine provided from all nicotine components within a given composition.
  • nicotine-polymer complex including resin and nicotine
  • amounts of nicotine-polymer complex (including resin and nicotine) incorporated within a given composition can range, e.g., from about 0.5% by weight to about 15% by weight, e.g., about 1% by weight to about 10% by weight, e.g., about 2% to about 8% by weight, based on the total weight of a composition/mixture to be included within a pouched product.
  • the nicotine component (calculated as the free base) is present in a concentration of at least about 0.001% by weight of the composition, such as in a range from about 0.001% to about 10%.
  • the nicotine component is present in a concentration from about 0.1% w/w to about 10% by weight, such as, e.g., from about from about 0.1% w/w, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight, calculated as the free base and based on the total weight of the composition.
  • the nicotine component is present in a concentration from about 0.1% w/w to about 3% by weight, such as, e.g., from about from about 0. 1% w/w to about 2.5%, from about 0.1% to about 2.0%, from about 0.1% to about 1.5%, or from about 0.1% to about 1% by weight, calculated as the free base and based on the total weight of the composition.
  • a basic amine -containing oral product configured for oral use which retains the initial basic amine content (e.g., nicotine content) during storage, and which delivers substantially the full amount of basic amine (e.g., nicotine) initially present in the oral product.
  • nicotine or other basic amine is employed in association with at least a portion of an organic acid or an alkali metal salt thereof (referred to herein as “ion pairing”).
  • Embodiments of the films disclosed herein can comprise at least one binder, a plasticizer, a basic amine, such as nicotine or a nicotine component; water; and an organic acid, an alkali metal salt of an organic acid, or a combination thereof, wherein the organic acid has a logP value of from about 1 to about 12, e.g., 1.4 to about 8.0.
  • the basic amine e.g., nicotine
  • the basic amine can be included in place of or in addition to other active ingredients described in more detail herein.
  • the basic amine present in the composition can exist in multiple forms, including ion paired, in solution (i.e., fully solvated), as the free base, as a cation, as a salt, or any combination thereof.
  • the relative amounts of the various components within the oral product composition may vary, and typically are selected so as to provide the desired sensory and performance characteristics to the oral product.
  • the association between the basic amine and at least a portion of the organic acid or the alkali metal salt thereof is in the form of an ion pair between the basic amine and a conjugate base of the organic acid.
  • Ion pairing describes the partial association of oppositely charged ions in relatively concentrated solutions to form distinct chemical species called ion pairs.
  • the strength of the association depends on the electrostatic force of attraction between the positive and negative ions (i.e., a protonated basic amine such as nicotine, and the conjugate base of the organic acid).
  • conjugate base is meant the base resulting from deprotonation of the corresponding acid (e.g., benzoate is the conjugate base of benzoic acid).
  • benzoate is the conjugate base of benzoic acid
  • the basic amine for example nicotine
  • the conjugate base of the organic acid exist at least partially in the form of an ion pair.
  • ion pairing may minimize chemical degradation of the basic amine and/or enhance the oral availability of the basic amine (e.g., nicotine).
  • alkaline pH values e.g., such as from about 7.5 to about 9
  • certain basic amines, for example nicotine are largely present in the free base form, which has relatively low water solubility, and low stability with respect to evaporation and oxidative decomposition, but high mucosal availability.
  • Lipophilicity is conveniently measured in terms of logP, the partition coefficient of a molecule between a lipophilic phase and an aqueous phase, usually octanol and water, respectively.
  • An octanol-water partitioning favoring distribution of a basic amine-organic acid ion pair into octanol is predictive of good absorption of the basic amine present in the composition through the oral mucosa.
  • alkaline pH values e.g., such as from about 7.5 to about 9
  • nicotine is largely present in the free base form (and accordingly, a high partitioning into octanol)
  • acidic pH values such as from about 6.5 to about 4
  • nicotine is largely present in a protonated form (and accordingly, a low partitioning into octanol).
  • An ion pair between certain organic acids e.g., having a logP value of from about 1.4 to about 8.0. such as from about 1.4 to about 4.5, allows nicotine partitioning into octanol consistent with that predicted for nicotine partitioning into octanol at a pH of 8.4.
  • the extent of ion pairing in the disclosed composition may vary based on, for example, pH, the nature of the organic acid, the concentration of nicotine, the concentration of the organic acid or conjugate base of the organic acid present in the composition, the water content of the composition, the ionic strength of the composition, and the like.
  • ion pairing is an equilibrium process influenced by the foregoing variables. Accordingly, quantification of the extent of ion pairing is difficult or impossible by calculation or direct observation.
  • the presence of ion pairing may be demonstrated through surrogate measures such as partitioning of the nicotine between octanol and water or membrane permeation of aqueous solutions of the basic amine plus organic acids and/or their conjugate bases.
  • organic acid refers to an organic (i.e., carbon-based) compound that is characterized by acidic properties.
  • organic acids are relatively weak acids (i.e., they do not dissociate completely in the presence of water), such as carboxylic acids (-CO2H) or sulfonic acids (- SO2OH).
  • reference to organic acid means an organic acid that is intentionally added.
  • an organic acid may be intentionally added as a specific composition ingredient as opposed to merely being inherently present as a component of another composition ingredient (e.g., the small amount of organic acid which may inherently be present in a composition ingredient, such as a tobacco material).
  • Suitable organic acids will typically have a range of lipophilicities (i.e., a polarity giving an appropriate balance of water and organic solubility).
  • lipophilicities of suitable organic acids as indicated by logP, will vary between about 1.4 and about 12 (more soluble in octanol than in water).
  • the organic acid has a logP value of from about 0.5 to about 12 or about 1 to about 12, e.g., from about 0.5, about 1.0, about 1.5, about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, or about 8, to about 8.5, about 9.0, about 9.5, about 10.0, about 10.5, about 11.0, about 11.5, or about 12.0.
  • suitable organic acids have a logP value of from about 1.7 to about 4, such as from about 2.0, about 2.5, or about 3.0, to about 3.5, or about 4.0.
  • the organic acid has a logP value of about 2.5 to about 3.5.
  • organic acids outside this range may also be utilized for various purposes and in various amounts, as described further herein below.
  • the organic acid may have a logP value of greater than about 4.5, such as from about 4.5 to about 8.0.
  • certain solvents or solubilizing agents e.g., inclusion in the composition of glycerin or propylene glycol
  • the organic acid has a logP value from about 3.0 to about 8.0, about 10.0, or even 12.0.
  • the presence of certain solvents or solubilizing agents may be beneficial in solubilizing organic acids and the corresponding salts or ion pairs thereof with the basic amine for highly lipophilic organic acids (e.g., higher than about 4.5).
  • moderately lipophilic organic acids e.g., logP of from about 1.4 to about 4.5
  • partitioning into octanol is predictive of favorable oral availability.
  • the organic acid has a log P value of from about 1.4 to about 4.5, such as about 1.5, about 2, about 2.5, about 3, about 3.5, about 4 or about 4.5.
  • the organic acid has a log P value of from about 2.5 to about 3.5.
  • the organic acid is a carboxylic acid or a sulfonic acid.
  • the carboxylic acid or sulfonic acid functional group may be attached to any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group having, for example, from one to twenty carbon atoms (C1-C20).
  • the organic acid is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl carboxylic or sulfonic acid.
  • alkyl refers to any straight chain or branched chain hydrocarbon.
  • the alkyl group may be saturated (i.e., having all sp 3 carbon atoms), or may be unsaturated (i.e., having at least one site of unsaturation).
  • unsaturated refers to the presence of a carbon-carbon, sp 2 double bond in one or more positions within the alkyl group.
  • Unsaturated alkyl groups may be mono- or polyunsaturated.
  • Representative straight chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl.
  • Branched chain alkyl groups include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and 2-methylbutyl.
  • Representative unsaturated alkyl groups include, but are not limited to, ethylene or vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl, 1- pentenyl, 2-pentenyl, 3 -methyl- 1-butenyl, 2 -methyl -2-butenyl, 2,3 -dimethyl -2-butenyl, and the like.
  • An alkyl group can be unsubstituted or substituted.
  • Cycloalkyl refers to a carbocyclic group, which may be mono- or bicyclic. Cycloalkyl groups include rings having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. A cycloalkyl group can be unsubstituted or substituted, and may include one or more sites of unsaturation (e.g., cyclopentenyl or cyclohexenyl).
  • aryl refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. An aryl group can be unsubstituted or substituted.
  • Heteroaryl and “heterocycloalkyl” as used herein refer to an aromatic or non-aromatic ring system, respectively, in which one or more ring atoms is a heteroatom, e.g. nitrogen, oxygen, and sulfur.
  • the heteroaryl or heterocycloalkyl group comprises up to 20 carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S.
  • a heteroaryl or heterocycloalkyl may be a monocycle having 3 to 7 ring members (for example, 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S) or a bicycle having 7 to 10 ring members (for example, 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S), for example: a bicyclo[4,5], [5,5], [5,6], or [6,6] system.
  • heteroaryl groups include by way of example and not limitation, pyridyl, thiazolyl, tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, IH-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-car
  • heterocycloalkyls include by way of example and not limitation, dihydroypyridyl, tetrahydropyridyl (piperidyl), tetrahydrothiophenyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2- pyrrolidonyl, tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, piperazinyl, quinuclidinyl, and morpholinyl. Heteroaryl and heterocycloalkyl groups can be unsubstituted or substituted.
  • Substituted as used herein and as applied to any of the above alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, means that one or more hydrogen atoms are each independently replaced with a substituent.
  • a group is described as “optionally substituted,” that group can be substituted with one or more of the above substituents, independently selected for each occasion.
  • the substituent may be one or more methyl groups or one or more hydroxyl groups.
  • the organic acid is an alkyl carboxylic acid.
  • alkyl carboxylic acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and the like.
  • the organic acid is an alkyl sulfonic acid.
  • alkyl sulfonic acids include propanesulfonic acid, heptanesulfonic acid, and octanesulfonic acid.
  • the alkyl carboxylic or sulfonic acid is substituted with one or more hydroxyl groups.
  • Non-limiting examples include glycolic acid, 4-hydroxybutyric acid, and lactic acid.
  • an organic acid may include more than one carboxylic acid group or more than one sulfonic acid group (e.g., two, three, or more carboxylic acid groups).
  • Non-limiting examples include oxalic acid, fumaric acid, maleic acid, and glutaric acid.
  • organic acids containing multiple carboxylic acids e.g., from two to four carboxylic acid groups
  • one or more of the carboxylic acid groups may be esterified.
  • Non-limiting examples include succinic acid monoethyl ester, monomethyl fumarate, monomethyl or dimethyl citrate, and the like.
  • the organic acid may include more than one carboxylic acid group and one or more hydroxyl groups.
  • Non-limiting examples of such acids include tartaric acid, citric acid, and the like.
  • the organic acid is an aryl carboxylic acid or an aryl sulfonic acid.
  • aryl carboxylic and sulfonic acids include benzoic acid, toluic acids, salicylic acid, benzenesulfonic acid, and p-toluene sulfonic acid.
  • organic acids which may be useful in certain embodiments include 2-(4-isobutylphenyl)propanoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2- oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid (L), aspartic acid (L), alpha-methylbutyric acid, camphoric acid (+), camphor- 10-sulfonic acid (+), cinnamic acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, furoic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, isovaleric acid, lac
  • suitable acids include, but are not limited to, the list of organic acids in Table 1. Table L Non-limiting examples of suitable organic acids
  • the organic acid is a mono ester of a di- or poly-acid, such as mono-octyl succinate, mono-octyl fumarate, or the like.
  • organic acid may further depend on additional properties in addition to consideration of the logP value. For example, an organic acid should be one recognized as safe for human consumption, and which has acceptable flavor, odor, volatility, stability, and the like. Determination of appropriate organic acids is within the purview of one of skill in the art.
  • the organic acid is benzoic acid, a toluic acid, benzenesulfonic acid, toluenesulfonic acid, hexanoic acid, heptanoic acid, decanoic acid, or octanoic acid.
  • the organic acid is benzoic acid, octanoic acid, or decanoic acid.
  • the organic acid is octanoic acid.
  • the organic acid is a mono ester of a dicarboxylic acid or a polycarboxylic acid.
  • the dicarboxylic acid is malonic acid, succinic acid, glutaric acid, adipic acid, fumaric acid, maleic acid, or a combination thereof.
  • the dicarboxylic acid is succinic acid, glutaric acid, fumaric acid, maleic acid, or a combination thereof.
  • the dicarboxylic acid is succinic acid, glutaric acid, or a combination thereof.
  • the alcohol forming the mono ester of the dicarboxylic acid is a lipophilic alcohol.
  • suitable lipophilic alcohols include, but are not limited to, octanol, menthol, and tocopherol.
  • the organic acid is an octyl mono ester of a dicarboxylic acid, such as monooctyl succinate, monooctyl fumarate, or the like.
  • the organic acid is a monomenthyl ester of a dicarboxylic acid.
  • Certain menthyl esters may be desirable in oral compositions as described herein by virtue of the cooling sensation they may provide upon use of the product comprising the composition.
  • the organic acid is monomenthyl succinate, monomenthyl fumarate, monomenthyl glutarate, or a combination thereof.
  • the organic acid is a monotocopheryl ester of a dicarboxylic acid. Certain tocopheryl esters may be desirable in oral compositions as described herein by virtue of the antioxidant effects they may provide.
  • the organic acid is tocopheryl succinate, tocopheryl fumarate, tocopheryl glutarate, or a combination thereof.
  • the organic acid is a carotenoid derivative having one or more carboxylic acids.
  • Carotenoids are tetraterpenes, meaning that they are produced from 8 isoprene molecules and contain 40 carbon atoms. Accordingly, they are usually lipophilic due to the presence of long unsaturated aliphatic chains, and are generally yellow, orange, or red in color.
  • Certain carotenoid derivatives can be advantageous in oral compositions by virtue of providing both ion pairing and serving as a colorant in the composition.
  • the organic acid is 2£',4£',6£',8£',10£',12£',14£',16Z,18£)-20- methoxy-4,8,13,17-tetramethyl-20-oxoicosa-2,4,6,8,10,12,14,16,18-nonaenoic acid (bixin) or an isomer thereof.
  • Bixin is an apocarotenoid found in annatto seeds from the achiote tree (Bixa orellana), and is the naturally occurring pigment providing the reddish orange color to annatto.
  • Bixin is soluble in fats and alcohols but insoluble in water, and is chemically unstable when isolated, converting via isomerization into the double bond isomer, trans -bixin (P-bixin), having the structure:
  • the organic acid is (2E,4E,6E,8E,10E,12E,14E,16E,18E)-4,8,13,17- tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioic acid (norbixin), a water-soluble hydrolysis product of bixin having tire structure:
  • more than one organic acid may be present.
  • the composition may comprise two, or three, or four, or more organic acids.
  • an organic acid contemplates mixtures of two or more organic acids.
  • the relative amounts of the multiple organic acids may vary.
  • a composition may comprise equal amounts of two, or three, or more organic acids, or may comprise different relative amounts.
  • certain organic acids e.g., citric acid or myristic acid
  • it is possible to include certain organic acids e.g., citric acid or myristic acid which have a logP value outside the desired range, when combined with other organic acids to provide the desired average logP range for the combination.
  • organic acids in the composition which have logP values outside the desired range for purposes such as, but not limited to, providing desirable organoleptic properties, stability, as flavor components, and the like.
  • certain lipophilic organic acids have undesirable flavor and or aroma characteristics which would preclude their presence as the sole organic acid (e.g., in equimolar or greater quantities relative to nicotine).
  • a combination of different organic acids may provide the desired ion pairing while the concentration of any single organic acid in the composition remains below the threshold which would be found objectionable from a sensory perspective.
  • the organic acid may comprise from about 1 to about 5 or more molar equivalents of benzoic acid relative to nicotine, combined with e.g., about 0.2 molar equivalents of octanoic acid or a salt thereof, and 0.2 molar equivalents of decanoic acid or a salt thereof.
  • the organic acid is a combination of any two organic acids selected from the group consisting of benzoic acid, a toluic acid, benzenesulfonic acid, toluenesulfonic acid, hexanoic acid, heptanoic acid, decanoic acid, and octanoic acid.
  • the organic acid is a combination of benzoic acid, octanoic acid, and decanoic acid, or benzoic and octanoic acid.
  • the composition comprises citric acid in addition to one or more of benzoic acid, a toluic acid, benzene sulfonic acid, toluene sulfonic acid, hexanoic acid, heptanoic acid, decanoic acid, and octanoic acid.
  • the composition comprises an organic acid which is a monoester of a dicarboxylic acid or is a carotenoid derivative having one or more carboxylic acids as described herein above, and further comprises an additional organic acid or salt thereof.
  • the additional organic acid is benzoic acid, an alkali metal salt thereof, or a combination thereof.
  • the composition comprises an alkali metal salt of an organic acid.
  • the organic acid may be present in the composition in the form of an alkali metal salt.
  • Suitable alkali metal salts include lithium, sodium, and potassium.
  • the alkali metal is sodium or potassium.
  • the alkali metal is sodium.
  • the composition comprises an organic acid and a sodium salt of the organic acid.
  • the composition comprises benzoic acid and sodium benzoate, octanoic acid and sodium octanoate, decanoic acid and sodium decanoate, or a combination thereof.
  • the weight ratio of the organic acid to the sodium salt (or other alkali metal) of the organic acid is from about 0. 1 to about 10, such as from about 0.1, about 0.25, about 0.3, about 0.5, about 0.75, or about 1, to about 2, about 5, or about 10.
  • both an organic acid and the sodium salt thereof are added to the other components of the composition, wherein the organic acid is added in excess of the sodium salt, in equimolar quantities with the sodium salt, or as a fraction of the sodium salt.
  • the relative amounts will be determined by the desired pH of the composition, as well as the desired ionic strength.
  • the organic acid may be added in a quantity to provide a desired pH level of the composition, while the alkali metal (e.g., sodium) salt is added in a quantity to provide the desired extent of ion pairing.
  • the quantity of organic acid (i.e., the protonated form) present in the composition, relative to the alkali metal salt or conjugate base form present in the composition will vary according to the pH of the composition and the pKa of the organic acid, as well as according to the actual relative quantities initially added to the composition.
  • the amount of organic acid or an alkali metal salt thereof present in the composition, relative to the basic amine (e.g., nicotine), may vary. Generally, as the concentration of the organic acid (or the conjugate base thereof) increases, the percent of nicotine that is ion paired with the organic acid increases. This typically increases the partitioning of the nicotine, in the form of an ion pair, into octanol versus water as measured by the logP (the login of the partitioning coefficient). In some embodiments, the composition comprises from about 0.05, about 0.1, about 1, about 1.5, about 2, or about 5, to about 10, about 15, or about 20 molar equivalents of the organic acid, the alkali metal salt thereof, or the combination thereof, relative to the nicotine component, calculated as free base nicotine.
  • the composition comprises from about 2 to about 10, or from about 2 to about 5 molar equivalents of the organic acid, the alkali metal salt thereof, or the combination thereof, to nicotine, on a free-base nicotine basis.
  • the organic acid, the alkali metal salt thereof, or the combination thereof is present in a molar ratio with the nicotine from about 2, about 3, about 4, or about 5, to about 6, about 7, about 8, about 9, or about 10.
  • more than one organic acid, alkali metal salt thereof, or both, are present, it is to be understood that such molar ratios reflect the totality of the organic acids present.
  • the organic acid inclusion is sufficient to provide a composition pH of from about 4.0 to about 9.0, such as from about 4.5 to about 7.0, or from about 5.5 to about 7.0, from about 4.0 to about 5.5, or from about 7.0 to about 9.0. In some embodiments, the organic acid inclusion is sufficient to provide a composition pH of from about 4.5 to about 6.5, for example, from about 4.5, about 5.0, or about 5.5, to about 6.0, or about 6.5.
  • the organic acid is provided in a quantity sufficient to provide a pH of the composition of from about 5.5 to about 6.5, for example, from about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0, to about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5.
  • a mineral acid e.g., hydrochloric acid, sulfuric acid, phosphoric acid, or the like
  • a higher pH is desirable, e.g., wherein the composition pH is above 7.
  • Certain specific embodiments are provided exhibiting a pH from 7 to 10, e.g., about 8 to about 10 or about 8 to about 9.
  • the organic acid is added as the free acid, either neat (i.e., native solid or liquid form) or as a solution in, e.g., water, to the other composition components.
  • the alkali metal salt of the organic acid is added, either neat or as a solution in, e.g., water, to the other composition components.
  • the organic acid and the basic amine e.g., nicotine
  • the organic acid and the basic amine are combined to form a salt, either before addition to the composition, or the salt is formed within and is present in the composition as such.
  • the organic acid and basic amine e.g., nicotine
  • the organic acid and basic amine are present as individual components in the composition, and form an ion pair upon contact with moisture (e.g., saliva in the mouth of the consumer).
  • the products or compositions of the disclosure can be characterized as free of any nicotine component (e.g., any embodiment as disclosed herein may be completely or substantially free of any nicotine component).
  • substantially free is meant that no nicotine has been intentionally added, beyond trace amounts that may be naturally present in e.g., a botanical material.
  • certain embodiments can be characterized as having less than 0.001% by weight of nicotine, or less than 0.0001%, or even 0% by weight of nicotine, calculated as the free base.
  • the active ingredient comprises a nicotine component (e.g., any product or composition of the disclosure, in addition to comprising any active ingredient or combination of active ingredients as disclosed herein, may further comprise a nicotine component).
  • a nicotine component e.g., any product or composition of the disclosure, in addition to comprising any active ingredient or combination of active ingredients as disclosed herein, may further comprise a nicotine component.
  • the active ingredient comprises one or more cannabinoids.
  • cannabinoid refers to a class of diverse natural or synthetic chemical compounds that acts on cannabinoid receptors (i.e., CB1 and CB2) in cells that alter neurotransmitter release in the brain.
  • Cannabinoids are cyclic molecules exhibiting particular properties such as the ability to easily cross the blood-brain barrier.
  • Cannabinoids may be naturally occurring (Phytocannabinoids) from plants such as cannabis, (endocannabinoids) from animals, or artificially manufactured (synthetic cannabinoids).
  • Cannabis species express at least 85 different phytocannabinoids, and these may be divided into subclasses, including cannabigerols, cannabichromenes, cannabidiols, tetrahydrocannabinols, cannabinols and cannabinodiols, and other cannabinoids, such as cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN) and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, can
  • the cannabinoid is selected from the group consisting of cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (THC), cannabinol (CBN) and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabmolic acid (THCA), tetrahydrocannabivarinic acid (THCV A), and mixtures thereof.
  • CBG
  • the cannabinoid comprises at least tetrahydrocannabinol (THC). In some embodiments, the cannabinoid is tetrahydrocannabinol (THC). In some embodiments, the cannabinoid comprises at least cannabidiol (CBD). In some embodiments, the cannabinoid is cannabidiol (CBD). In some embodiments, the CBD is synthetic CBD.
  • the cannabinoid e.g., CBD
  • CBD cannabinoid
  • An isolate is an extract from a plant, such as cannabis, where the active material of interest (in this case the cannabinoid, such as CBD) is present in a high degree of purity, for example greater than 95%, greater than 96%, greater than 97%, greater than 98%, or around 99% purity.
  • the cannabinoid is an isolate of CBD in a high degree of purity, and the amount of any other cannabinoid in the composition is no greater than about 1% by weight of the composition, such as no greater than about 0.5% by weight of the composition, such as no greater than about 0.1% by weight of the composition, such as no greater than about 0.01% by weight of the composition.
  • a cannabinoid e.g., CBD
  • cannabimimetic is typically in a concentration of at least about 0.001%, at least about 0.01%, or at least about 0.1% by weight of the composition, such as in a range from about 0.001% to about 2% by weight of the composition, e.g., about 0.1% to about 1.5% or about 0.4% to about 1.5% by weight.
  • the cannabinoid e.g., CBD
  • the cannabinoid is present in an amount of about 0.1% to about 30%, such as, e.g., from about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, or about 30% by weight, based on the total weight of the composition.
  • the choice of cannabinoid and the particular percentages thereof which may be present within the disclosed composition will vary depending upon the desired flavor, texture, and other characteristics of the composition.
  • the active ingredient can include a cannabimimetic, which is a class of compounds derived from plants other than cannabis that have biological effects on the endocannabinoid system similar to cannabinoids.
  • cannabimimetic is a class of compounds derived from plants other than cannabis that have biological effects on the endocannabinoid system similar to cannabinoids. Examples include yangonin, alpha-amyrin or beta-amyrin (also classified as terpenes), cyanidin, curcumin (tumeric), catechin, quercetin, salvinorin A, N-acylethanolamines, and N-alkylamide lipids. Such compounds can be used in the same amounts and ratios noted herein for cannabinoids.
  • terpenes Active ingredients suitable for use in the present disclosure can also be classified as terpenes, many of which are associated with biological effects, such as calming effects.
  • Terpenes are understood to have the general formula of (CM h)n and include monoterpenes, sesquiterpenes, and diterpenes.
  • Terpenes can be acyclic, monocyclic or bicyclic in structure. Some terpenes provide an entourage effect when used in combination with cannabinoids or cannabimimetics.
  • Examples include beta-caryophyllene, linalool, limonene, beta-citronellol, linalyl acetate, pinene (alpha or beta), geraniol, carvone, eucalyptol, menthone, iso-menthone, piperitone, myrcene, beta-bourbonene, and germacrene, which may be used singly or in combination.
  • the terpene is a terpene derivable from a phytocannabinoid producing plant, such as a plant from the strain of the cannabis sativa species, such as hemp.
  • Suitable terpenes in this regard include so-called “CIO” terpenes, which are those terpenes comprising 10 carbon atoms, and so-called “Cl 5” terpenes, which are those terpenes comprising 15 carbon atoms.
  • the active ingredient comprises more than one terpene.
  • the active ingredient may comprise one, two, three, four, five, six, seven, eight, nine, ten or more terpenes as defined herein.
  • the terpene is selected from pinene (alpha and beta), geraniol, linalool, limonene, carvone, eucalyptol, menthone, iso-menthone, piperitone, myrcene, beta-bourbonene, germacrene and mixtures thereof.
  • the active ingredient comprises an active pharmaceutical ingredient (API).
  • API can be any known agent adapted for therapeutic, prophylactic, or diagnostic use. These can include, for example, synthetic organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, phospholipids, inorganic compounds (e.g., magnesium, selenium, zinc, nitrate), neurotransmitters or precursors thereof (e.g., serotonin, 5 -hydroxytryptophan, oxitriptan, acetylcholine, dopamine, melatonin), and nucleic acid sequences, having therapeutic, prophylactic, or diagnostic activity.
  • synthetic organic compounds proteins and peptides, polysaccharides and other sugars, lipids, phospholipids, inorganic compounds (e.g., magnesium, selenium, zinc, nitrate), neurotransmitters or precursors thereof (e.g., serotonin, 5 -hydroxytryptophan, oxitriptan, ace
  • Non-limiting examples of APIs include analgesics and antipyretics (e.g., acetylsalicylic acid, acetaminophen, 3-(4-isobutylphenyl)propanoic acid), phosphatidylserine, myoinositol, docosahexaenoic acid (DHA, Omega-3), arachidonic acid (AA, Omega-6), S-adenosylmethionine (SAM), beta-hydroxy- beta-methylbutyrate (HMB), citicoline (cytidine-5'-diphosphate-choline), and cotinine.
  • the active ingredient comprises citicoline.
  • the active ingredient is a combination of citicoline, caffeine, theanine, and ginseng. In some embodiments, the active ingredient comprises sunflower lecithin. In some embodiments, the active ingredient is a combination of sunflower lecithin, caffeine, theanine, and ginseng.
  • an API is typically at a concentration of from about 0.001% w/w to about 10% by weight, such as, e.g., from about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1% w/w, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1%, to about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight, based on the total weight of the composition.
  • the composition is substantially free of any API.
  • substantially free of any API means that the composition does not contain, and specifically excludes, the presence of any API as defined herein, such as any Food and Drug Administration (FDA) approved therapeutic agent intended to treat any medical condition.
  • FDA Food and Drug Administration
  • the mixture may include a tobacco material.
  • the tobacco material can vary in species, type, and form. Generally, the tobacco material is obtained from for a harvested plant of the Nicotiana species.
  • Example Nicotiana species include N. tabacum, N. rustica, N. alata, N. arentsii, N. excelsior, N. forgetiana, N. glauca, N. glutinosa, N. gossei, N. kawakamii, N. knightiana, N. langsdorffi, N. otophora, N. setchelli, N. sylvestris, N. tomentosa, N. tomentosiformis, N. undulata, N.
  • Nicotiana species from which suitable tobacco materials can be obtained can be derived using genetic-modification or crossbreeding techniques (e.g., tobacco plants can be genetically engineered or crossbred to increase or decrease production of components, characteristics or attributes). See, for example, the types of genetic modifications of plants set forth in US Pat. Nos. 5,539,093 to Fitzmaurice et al.; 5,668,295 to Wahab et al.; 5,705,624 to Fitzmaurice et al.; 5,844,119 to Weigl; 6,730,832 to Dominguez et al.; 7,173,170 to Liu et al.; 7,208,659 to Colliver et al.
  • the Nicotiana species can, in some embodiments, be selected for the content of various compounds that are present therein. For example, plants can be selected on the basis that those plants produce relatively high quantities of one or more of the compounds desired to be isolated therefrom.
  • plants of the Nicotiana species e.g., Galpao commun tobacco
  • Tobacco plants can be grown in greenhouses, growth chambers, or outdoors in fields, or grown hydroponically.
  • the plant of the Nicotiana species can be included within a mixture as disclosed herein.
  • virtually all of the plant e.g., the whole plant
  • various parts or pieces of the plant can be harvested or separated for further use after harvest.
  • the flower, leaves, stem, stalk, roots, seeds, and various combinations thereof, can be isolated for further use or treatment.
  • the tobacco material comprises tobacco leaf (lamina).
  • the mixture disclosed herein can include processed tobacco parts or pieces, cured and aged tobacco in essentially natural lamina and/or stem form, a tobacco extract, extracted tobacco pulp (e.g., using water as a solvent), or a mixture of the foregoing (e.g., a mixture that combines extracted tobacco pulp with granulated cured and aged natural tobacco lamina).
  • the tobacco material comprises solid tobacco material selected from the group consisting of lamina and stems.
  • the tobacco that is used for the mixture most preferably includes tobacco lamina, or a tobacco lamina and stem mixture (of which at least a portion is smoke-treated).
  • Portions of the tobaccos within the mixture may have processed forms, such as processed tobacco stems (e.g., cut-rolled stems, cut-rolled-expanded stems or cut-puffed stems), or volume expanded tobacco (e.g., puffed tobacco, such as dry ice expanded tobacco (DIET)). See, for example, the tobacco expansion processes set forth in US Pat. Nos.
  • the d mixture optionally may incorporate tobacco that has been fermented. See, also, the types of tobacco processing techniques set forth in PCT W02005/063060 to Atchley et al., which is incorporated herein by reference.
  • the tobacco material is typically used in a form that can be described as particulate (i.e., shredded, ground, granulated, or powder form).
  • the manner by which the tobacco material is provided in a finely divided or powder type of form may vary.
  • plant parts or pieces are comminuted, ground or pulverized into a particulate form using equipment and techniques for grinding, milling, or the like.
  • the plant material is relatively dry in form during grinding or milling, using equipment such as hammer mills, cutter heads, air control mills, or the like.
  • tobacco parts or pieces may be ground or milled when the moisture content thereof is less than about 15 weight percent or less than about 5 weight percent.
  • the tobacco material is employed in the form of parts or pieces that have an average particle size between 1.4 millimeters and 250 microns.
  • the tobacco particles may be sized to pass through a screen mesh to obtain the particle size range required.
  • air classification equipment may be used to ensure that small sized tobacco particles of the desired sizes, or range of sizes, may be collected.
  • differently sized pieces of granulated tobacco may be mixed together.
  • tobacco parts or pieces are comminuted, ground or pulverized into a powder type of form using equipment and techniques for grinding, milling, or the like.
  • the tobacco is relatively dry in form during grinding or milling, using equipment such as hammer mills, cutter heads, air control mills, or the like.
  • tobacco parts or pieces may be ground or milled when the moisture content thereof is less than about 15 weight percent to less than about 5 weight percent.
  • the tobacco plant or portion thereof can be separated into individual parts or pieces (e.g., the leaves can be removed from the stems, and/or the stems and leaves can be removed from the stalk).
  • the harvested plant or individual parts or pieces can be further subdivided into parts or pieces (e.g., the leaves can be shredded, cut, comminuted, pulverized, milled or ground into pieces or parts that can be characterized as filler-type pieces, granules, particulates or fine powders).
  • the plant, or parts thereof can be subjected to external forces or pressure (e.g., by being pressed or subjected to roll treatment).
  • the plant or portion thereof can have a moisture content that approximates its natural moisture content (e.g., its moisture content immediately upon harvest), a moisture content achieved by adding moisture to the plant or portion thereof, or a moisture content that results from the drying of the plant or portion thereof.
  • powdered, pulverized, ground or milled pieces of plants or portions thereof can have moisture contents of less than about 25 weight percent, often less than about 20 weight percent, and frequently less than about 15 weight percent.
  • tobacco materials that can be employed include flue-cured or Virginia (e.g., K326), burley, sun-cured (e.g., Indian Kumool and Oriental tobaccos, including Katerini, Prelip, Komotini, Xanthi and Yambol tobaccos), Maryland, dark, dark-fired, dark air cured (e.g., Madole, Passanda, Cubano, Jatin and Bezuki tobaccos), light air cured (e.g., North Wisconsin and Galpao tobaccos), Indian air cured, Red Russian and Rustica tobaccos, as well as various other rare or specialty tobaccos and various blends of any of the foregoing tobaccos.
  • the tobacco material may also have a so-called "blended" form.
  • the tobacco material may include a mixture of parts or pieces of flue-cured, burley (e.g., Malawi burley tobacco) and Oriental tobaccos (e.g., as tobacco composed of, or derived from, tobacco lamina, or a mixture of tobacco lamina and tobacco stem).
  • a representative blend may incorporate about 30 to about 70 parts burley tobacco (e.g., lamina, or lamina and stem), and about 30 to about 70 parts flue cured tobacco (e.g., stem, lamina, or lamina and stem) on a dry weight basis.
  • example tobacco blends incorporate about 75 parts flue-cured tobacco, about 15 parts burley tobacco, and about 10 parts Oriental tobacco; or about 65 parts flue-cured tobacco, about 25 parts burley tobacco, and about 10 parts Oriental tobacco; or about 65 parts flue-cured tobacco, about 10 parts burley tobacco, and about 25 parts Oriental tobacco; on a dry weight basis.
  • Other example tobacco blends incorporate about 20 to about 30 parts Oriental tobacco and about 70 to about 80 parts flue-cured tobacco on a dry weight basis.
  • Tobacco materials used in the present disclosure can be subjected to, for example, fermentation, bleaching, and the like.
  • the tobacco materials can be, for example, irradiated, pasteurized, or otherwise subjected to controlled heat treatment.
  • controlled heat treatment processes are detailed, for example, in US Pat. No. 8,061,362 to Mua et al., which is incorporated herein by reference.
  • tobacco materials can be treated with water and an additive capable of inhibiting reaction of asparagine to form acrylamide upon heating of the tobacco material (e.g., an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, cysteine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, compositions incorporating di- and trivalent cations, asparaginase, certain non-reducing saccharides, certain reducing agents, phenolic compounds, certain compounds having at least one free thiol group or functionality, oxidizing agents, oxidation catalysts, natural plant extracts (e.g., rosemary extract), and combinations thereof.
  • an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, cysteine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, compositions incorporating di
  • the type of tobacco material is selected such that it is initially visually lighter in color than other tobacco materials to some degree (e.g., whitened or bleached).
  • Tobacco pulp can be whitened in certain embodiments according to any means known in the art.
  • bleached tobacco material produced by various whitening methods using various bleaching or oxidizing agents and oxidation catalysts can be used.
  • Example oxidizing agents include peroxides (e.g., hydrogen peroxide), chlorite salts, chlorate salts, perchlorate salts, hypochlorite salts, ozone, ammonia, potassium permanganate, and combinations thereof.
  • Example oxidation catalysts are titanium dioxide, manganese dioxide, and combinations thereof.
  • the whitened tobacco material can have an ISO brightness of at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%. In some embodiments, the whitened tobacco material can have an ISO brightness in the range of about 50% to about 90%, about 55% to about 75%, or about 60% to about 70%. ISO brightness can be measured according to ISO 3688: 1999 or ISO 2470-1:2016.
  • the whitened tobacco material can be characterized as lightened in color (e.g., "whitened") in comparison to an untreated tobacco material.
  • White colors are often defined with reference to the International Commission on Illumination's (CIE's) chromaticity diagram.
  • CIE's International Commission on Illumination's
  • the whitened tobacco material can, in certain embodiments, be characterized as closer on the chromaticity diagram to pure white than an untreated tobacco material.
  • the tobacco material can be treated to extract a soluble component of the tobacco material therefrom.
  • tobacco extract refers to the isolated components of a tobacco material that are extracted from solid tobacco pulp by a solvent that is brought into contact with the tobacco material in an extraction process.
  • extraction techniques of tobacco materials can be used to provide a tobacco extract and tobacco solid material. See, for example, the extraction processes described in US Pat. Appl. Pub. No. 2011/0247640 to Beeson et al., which is incorporated herein by reference.
  • Other example techniques for extracting components of tobacco are described in US Pat. Nos. 4,144,895 to Fiore; 4,150,677 to Osborne, Jr.
  • Typical inclusion ranges for tobacco materials can vary depending on the nature and type of the tobacco material, and the intended effect on the final mixture (or composition), with an example range of up to about 30% by weight (or up to about 20% by weight or up to about 10% by weight or up to about 5% by weight), based on total weight of the mixture (e.g., about 0. 1 to about 15% by weight).
  • a tobacco material e.g., a whitened tobacco material
  • a relatively small amount e.g., about 0.01% to about 0. 1% by weight.
  • the products of the disclosure can be characterized as completely free or substantially free of tobacco material (other than purified nicotine which may optionally be included as an active ingredient).
  • tobacco material other than purified nicotine which may optionally be included as an active ingredient.
  • certain embodiments can be characterized as having less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight of tobacco material, or 0% by weight of tobacco material.
  • Other additives can be characterized as having less than 1% by weight, or less than 0.5% by weight, or less than 0.1% by weight of tobacco material, or 0% by weight of tobacco material.
  • additives can be included in the disclosed mixture (or composition).
  • the mixture can be processed, blended, formulated, combined and/or mixed with other materials or ingredients.
  • the additives can be artificial, or can be obtained or derived from herbal or biological sources.
  • further types of additives include thickening or gelling agents (e.g., fish gelatin), emulsifiers, preservatives (e.g., potassium sorbate and the like), zinc or magnesium salts selected to be relatively water soluble for compositions with greater water solubility (e.g., magnesium or zinc gluconate) or selected to be relatively water insoluble for compositions with reduced water solubility (e.g., magnesium or zinc oxide), disintegration aids, or combinations thereof.
  • thickening or gelling agents e.g., fish gelatin
  • emulsifiers e.g., preservatives (e.g., potassium sorbate and the like)
  • zinc or magnesium salts selected to be relatively water soluble for compositions with greater water solub
  • Typical inclusion ranges for such additional additives can vary depending on the nature and function of the additive and the intended effect on the final mixture, with an example range of up to about 10% by weight, based on total weight of the mixture (e.g., about 0. 1 to about 5% by weight).
  • additives can be employed together (e.g., as additive formulations) or separately (e.g., individual additive components can be added at different stages involved in the preparation of the final mixture).
  • aforementioned types of additives may be encapsulated as provided in the final product or mixture.
  • Example encapsulated additives are described, for example, in WO2010/132444 to Atchley, which has been previously incorporated by reference herein.
  • any one or more of a filler component, a tobacco material, and the overall oral product described herein can be described as a particulate material.
  • the term "particulate” refers to a material in the form of a plurality of individual particles, some of which can be in the form of an agglomerate of multiple particles, wherein the particles have an average length to width ratio less than 2: 1, such as less than 1.5: 1, such as about 1: 1.
  • the particles of a particulate material can be described as substantially spherical or granular.
  • the particle size of a particulate material may be measured by sieve analysis.
  • sieve analysis is a method used to measure the particle size distribution of a particulate material.
  • sieve analysis involves a nested column of sieves which comprise screens, preferably in the form of wire mesh cloths. A pre-weighed sample may be introduced into the top or uppermost sieve in the column, which has the largest screen openings or mesh size (i.e. the largest pore diameter of the sieve). Each lower sieve in the column has progressively smaller screen openings or mesh sizes than the sieve above.
  • a receiver portion to collect any particles having a particle size smaller than the screen opening size or mesh size of the bottom or lowermost sieve in the column (which has the smallest screen opening or mesh size).
  • the column of sieves may be placed on or in a mechanical agitator.
  • the agitator causes the vibration of each of the sieves in the column.
  • the mechanical agitator may be activated for a pre-determined period of time in order to ensure that all particles are collected in the correct sieve.
  • the column of sieves is agitated for a period of time from 0.5 minutes to 10 minutes, such as from 1 minute to 10 minutes, such as from 1 minute to 5 minutes, such as for approximately 3 minutes.
  • the screen opening sizes or mesh sizes for each sieve in the column used for sieve analysis may be selected based on the granularity or known maximum/minimum particle sizes of the sample to be analysed.
  • a column of sieves may be used for sieve analysis, wherein the column comprises from 2 to 20 sieves, such as from 5 to 15 sieves.
  • a column of sieves may be used for sieve analysis, wherein the column comprises 10 sieves.
  • the largest screen opening or mesh sizes of the sieves used for sieve analysis may be 1000 pm, such as 500 pm, such as 400 pm, such as 300 pm.
  • any particulate material referenced herein can be characterized as having at least 50% by weight of particles with a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm.
  • at least 60% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm.
  • At least 70% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm. In some embodiments, at least 80% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm.
  • At least 90% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm. In some embodiments, at least 95% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm.
  • At least 99% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm. In some embodiments, approximately 100% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of no greater than about 1000 pm, such as no greater than about 500 pm, such as no greater than about 400 pm, such as no greater than about 350 pm, such as no greater than about 300 pm.
  • At least 50% by weight, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, such as at least 90% by weight, such as at least 95% by weight, such as at least 99% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of from about 0.01 pm to about 1000 pm, such as from about 0.05 pm to about 750 pm, such as from about 0.1 pm to about 500 pm, such as from about 0.25 pm to about 500 pm.
  • At least 50% by weight, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, such as at least 90% by weight, such as at least 95% by weight, such as at least 99% by weight of the particles of any particulate material referenced herein have a particle size as measured by sieve analysis of from about 10 pm to about 400 pm, such as from about 50 pm to about 350 pm, such as from about 100 pm to about 350 pm, such as from about 200 pm to about 300 pm.
  • the manner by which the various components of the mixture are combined may vary.
  • the overall mixture of various components with e.g., powdered mixture components may be relatively uniform in nature.
  • the components noted above, which may be in liquid or dry solid form, can be admixed in a pretreatment step prior to mixture with any remaining components of the mixture, or simply mixed together with all other liquid or dry ingredients.
  • the various components of the mixture may be contacted, combined, or mixed together using any mixing technique or equipment known in the art. Any mixing method that brings the mixture ingredients into intimate contact can be used, such as a mixing apparatus featuring an impeller or other structure capable of agitation.
  • mixing equipment examples include casing drums, conditioning cylinders or drums, liquid spray apparatus, conical-type blenders, ribbon blenders, mixers available as FKM130, FKM600, FKM1200, FKM2000 and FKM3000 from Littleford Day, Inc., Plough Share types of mixer cylinders, Hobart mixers, and the like. See also, for example, the types of methodologies set forth in US Pat. Nos. 4, 148,325 to Solomon et al.; 6,510,855 to Korte et al.; and 6,834,654 to Williams, each of which is incorporated herein by reference.
  • the components forming the mixture are prepared such that the mixture thereof may be used in a starch molding process for forming the mixture.
  • the compositions may be prepared such that the composition mixture may be used in a starchless molding process or a starch-based molding process.
  • Example types of molds that may be used in a production process include, for example, starch molds, starchless molds, pectin molds, plastic tray molds, silicone tray molds, metallic tray molds, neoprene tray molds, and the like.
  • the capsule(s) can be included within the particulate composition by various means.
  • the capsule(s) may be included during preparation (e.g., mixing) of the particulate composition components.
  • the capsule(s) may be included after preparation (e.g., mixing) but prior to inclusion within an outer water-permeable pouch.
  • the capsule(s) may be included after preparation (e.g., mixing) and inclusion of the particulate composition within an outer water-permeable pouch.
  • the capsule is added when the pouch is being formed, i.e., a particulate composition is mixed and the capsule(s) and particulate composition are substantially simultaneously added within the outer water-permeable pouch.
  • the particulate composition is mixed and the capsule(s) are incorporated into the particulate composition; the capsule(s)-containing particulate composition is then added within the water-permeable pouch.
  • a moisture -permeable packet or pouch can act as a container for use of the composition within.
  • the pouch provides a liquid-permeable container of a type that may be considered to be similar in character to the mesh-like type of material that is used for the construction of a tea bag.
  • flavoring ingredients, disintegration aids, and other desired components may be incorporated within, or applied to, the pouch material.
  • the composition/construction of such packets or pouches, such as the container pouch 20/50/70 in the embodiments illustrated in FIGs. 1, 4, and 5, respectively, may be varied as noted herein.
  • suitable packets, pouches or containers of the type used for the manufacture of smokeless tobacco products are available under the tradenames CatchDry, Ettan, General, Granit, Goteborgs Rape, Grovsnus White, Metropol Kaktus, Mocca Anis, Mocca Mint, Mocca Wintergreen, Kicks, Probe, Prince, Skruf and TreAnkrare.
  • a pouch type of product similar in shape and form to various embodiments of a pouched product described herein is commercially available as ZONNIC (distributed by Niconovum AB).
  • pouch type products generally similar in shape and form to various embodiments of a pouched product are set forth as snuff bag compositions E-J in Example 1 of PCT WO 2007/104573 to Axelsson et al., which is incorporated herein by reference, which are produced using excipient ingredients and processing conditions that can be used to manufacture pouched products as described herein.
  • the pouches can be formed from a fleece material, e.g., fibrous nonwoven webs.
  • the term “fiber” is defined as a basic element of textiles. Fibers are often in the form of a rope- or stringlike element.
  • the term “fiber” is intended to include fibers, filaments, continuous filaments, staple fibers, and the like.
  • multicomponent fibers refers to fibers that comprise two or more components that are different by physical or chemical nature, including bicomponent fibers. Specifically, the term “multicomponent fibers” includes staple and continuous fibers prepared from two or more polymers present in discrete structured domains in the fiber, as opposed to blends where the domains tend to be dispersed, random or unstructured.
  • a “fleece material” as used herein may be formed from various types of fibers (e.g., cellulosic fibers; such as viscose fibers, regenerated cellulose fibers, cellulose fibers, and wood pulps; cotton fibers; other natural fibers; or polymer/synthetic-type fibers) capable of being formed into a traditional fleece fabrics or other traditional pouch materials.
  • fibers e.g., cellulosic fibers; such as viscose fibers, regenerated cellulose fibers, cellulose fibers, and wood pulps; cotton fibers; other natural fibers; or polymer/synthetic-type fibers
  • fleece materials may be provided in the form of a woven or nonwoven fabric. Suitable types of fleece materials, for example, are described in U.S. Patent No. 8,931,493 to Sebastian et al.; US Patent App. Pub. No. 2016/0000140 to Sebastian et al.; and US Patent App. Pub. No. 2016/0073689
  • nonwoven is used herein in reference to fibrous materials, webs, mats, batts, or sheets in which fibers are aligned in an undefined or random orientation.
  • the nonwoven fibers are initially presented as unbound fibers or filaments.
  • An important step in the manufacturing of nonwovens involves binding the various fibers or filaments together.
  • the manner in which the fibers or filaments are bound can vary, and include thermal, mechanical and chemical techniques that are selected in part based on the desired characteristics of the final product, as discussed in more detail below.
  • the pouch material can be dissolvable (i.e., orally ingestible) such that under conditions of normal use (i.e., upon contact with saliva in the mouth of a user), the pouch material dissolves.
  • the pouch material will dissolve after a significant amount of the soluble components of the composition within the pouch (e.g., active ingredient(s) and/or flavorant(s)) permeate through the pouch material into the mouth of the user.
  • the pouch material can be configured to dissolve at a rate such that the pouch material holds the composition together for a period of time sufficient to allow for the release of substantially all water soluble components.
  • the composition within the pouch material can also be dissolvable.
  • the pouch material can be configured to dissolve at a rate similar to the rate at which the composition dissolves.
  • the pouch material can be adapted to or configured to at least partially dissolve or completely dissolve in about 5 minutes or longer, about 15 minutes or longer, about 30 minutes or longer, or about an hour or longer.
  • the pouch material can be adapted to or configured to at least partially dissolve or completely dissolve in no less than 30 minutes, no less than 45 minutes, or no less than an hour.
  • the pouch material may be adapted to or configured to at least partially dissolve or completely dissolve in a time of about 30 seconds to about 30 minutes, about 1 minute to about 25 minutes, about 5 minutes to about 20 minutes, or about 5 minutes to about 15 minutes.
  • a pouched product comprising a dissolvable pouch material can provide environmental advantages.
  • dissolvable pouch materials can include, but are not limited to, spun or nonwoven alginate fibers, gluten fibers, mini-perforated flat sheets derived from alginate, carrageenan, and other polymer binders, and combinations thereof.
  • the dissolution rate of the pouch material can be controlled by the use of cross-linking technology between alginate or pectin and calcium salts, for example.
  • the dissolvable pouch material can include fast dissolving fibers formed using an electrospinning process (e.g., solution-based electrospinning) with hydrophilic polymers.
  • the fibers within the fleece material may include, but are not limited to, a polymer selected from the group consisting of polyglycolic acid, polylactic acid, polyhydroxyalkanoates, polycaprolactone, polybutylene succinate, polybutylene succinate adipate, and copolymers thereof.
  • the fibers within the fleece material may be selected from the groups consisting wool, cotton, fibers made of cellulosic material, such as regenerated cellulose, cellulose acetate, cellulose triacetate, cellulose nitrate, ethyl cellulose, cellulose acetate propionate, cellulose acetate butyrate, hydroxypropyl cellulose, methyl hydroxypropyl cellulose, protein fibers, and the like. See also, the fiber types set forth in US Pat. Appl. Pub. No. 2014/0083438 to Sebastian et al., which is incorporated by reference herein.
  • the pouch material can include a polymer selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, and combinations thereof.
  • Regenerated cellulose fibers can be particularly advantageous, and are typically prepared by extracting non-cellulosic compounds from wood, contacting the extracted wood with caustic soda, followed by carbon disulfide and then by sodium hydroxide, giving a viscous solution. The solution is subsequently forced through spinneret heads to create viscous threads of regenerated fibers.
  • Example methods for the preparation of regenerated cellulose are provided in U.S. Pat. No. 4,237,274 to Eeoni et al; U.S. Pat. No. 4,268,666 to Baldini et al; U.S. Pat. No.
  • the fibers used in the nonwoven web according to the present disclosure can vary, and include fibers having any type of cross-section, including, but not limited to, circular, rectangular, square, oval, triangular, and multilobal.
  • the fibers can have one or more void spaces, wherein the void spaces can have, for example, circular, rectangular, square, oval, triangular, or multilobal cross- sections.
  • the fibers can be selected from single -component (i.e., uniform in composition throughout the fiber) or multicomponent fiber types including, but not limited to, fibers having a sheath/core structure and fibers having an islands-in-the-sea structure, as well as fibers having a side-by-side, segmented pie, segmented cross, segmented ribbon, or tipped multilobal cross-sections.
  • the physical parameters of the fibers present in the nonwoven web can vary.
  • the fibers used in the nonwoven web can have varying size (e.g., length, dpf) and crimp characteristics.
  • fibers used in the nonwoven web can be nano fibers, sub-micron fibers, and/or micron-sized fibers.
  • fibers of the nonwoven webs useful herein can measure about 1.5 dpf to about 2.0 dpf, or about 1.6 dpf to about 1.90 dpf.
  • each fiber can be a staple fiber.
  • Each fiber length can measure about 35 mm to about 60 mm, or about 38 mm to about 55 mm, for example.
  • each fiber can measure about 4-10 crimps per cm, or about 5-8 crimps per cm. It can be advantageous for all fibers in the nonwoven web to have similar fiber size and crimp attributes to ensure favorable blending and orientation of the fibers in the nonwoven web.
  • the fibrous webs can have varying thicknesses, porosities and other parameters.
  • the nonwoven web can be formed such that the fiber orientation and porosity of the pouched product formed therefrom can retain the composition adapted for oral use that is enclosed within the outer water-permeable pouch, but can also allow the flavors of the composition to be enjoyed by the consumer.
  • the fibrous webs can have a basis weight of about 20 gsm to about 60 gsm, about 20 gsm to about 35 gsm, or about 25 gsm to about 30 gsm. In a preferred embodiment, the fibrous web can have a basis weight of about 28 gsm.
  • Basis weight of a fabric can be measured using ASTM D3776/D3776M- 09a(2013) (Standard Test Methods for Mass Per Unit Area (Weight) of Fabric), for example.
  • the fibrous web can have a thickness of about 0. 1 mm to about 0. 15 mm (e.g., about 0. 11 mm).
  • the fibrous web can have an elongation of about 70% to about 80%, e.g., about 78%.
  • the fibrous web can have a peak load of about 4 lbs. to about 8 lbs., e.g., about 5.5 lbs.
  • Elongation and breaking strength of textile fabrics can be measured using ASTM D5034-09(2013) (Standard Test Method for Breaking Strength and Elongation of Textile Fabrics (Grab Test)), for example.
  • the fibrous web can have a Tensile Energy Absorption (TEA) of about 35 to about 40, e.g., about 37.
  • the fibrous web can have a porosity of greater than about 10,000 ml/min/cm 2 .
  • TEA can be measured, for example, as the work done to break the specimen under tensile loading per lateral area of the specimen.
  • Porosity, or air permeability of textile fabrics can be measured using ASTM D737-04(2012) (Standard Test method for Air Permeability of Textile Fabrics), for example.
  • the outer water-permeable pouch is made from a nonwoven web as described above.
  • a pouch is constructed of a single layer of the nonwoven web.
  • the pouch material comprises a multilayer composite made up of two or more nonwoven layers, each layer being orally ingestible. Each nonwoven layer can be formed by processes discussed below.
  • a first layer can be relatively hydrophilic and a second layer can be relatively hydrophobic (compared to each other).
  • an outer water-permeable pouch can comprise an outer hydrophilic layer and an inner hydrophobic layer that can be in contact with the composition adapted for oral use.
  • the hydrophobic layer can, during storage of the pouched product, retain any moisture in the composition adapted for oral use such that flavors in the composition are not lost due to moisture loss.
  • capillaries in the hydrophobic layer can wick out moisture into the mouth of the user, such that flavors are released into the oral cavity when used.
  • the pouch material can enhance storage stability without significantly compromising the enjoyment of the product by the end user.
  • the relatively hydrophilic layer could be located on the interior of the multi-layer structure.
  • the two layers can be formed into a multi-layer composite nonwoven material using any means known in the art, such as by attaching the two layers together using adhesive or stitching.
  • the hydrophobicity of a textile material can be evaluated, for example, by measuring the contact angles between a drop of liquid and the surface of a textile material, as is known in the art.
  • the pouch material can comprise a flavor component which can be applied to the nonwoven layer in any conventional manner such as by coating, printing, and the like.
  • the flavor within an outer pouch material can differ from a flavor contained within the internal composition adapted for oral use.
  • the pouch material can have a first flavor component and after the pouch material has dissolved, more moisture can reach the composition within the pouch material and a flavor component within the composition can be enhanced.
  • the product can be designed to provide multiple, different sensory experiences, a first sensory experience where the flavor in the outer pouch material transitions into the mouth of the user and a second sensory experience, typically occurring later in time, where the flavor of the internal composition transitions into the mouth of the user.
  • a heat sealable binder coating or a binder material may be added to the fibers prior to, during, or after forming the fleece material.
  • heat sealable binder coatings refers to coating materials, such as acrylic polymer compositions, applied to a substrate (e.g., a nonwoven web or fleece material) and which are capable of sealing seams of individual pouches upon heating.
  • a binder material can be added to the web fibers before or during the laying of the fibrous web (i.e., before the fibrous web is bonded to form a fleece material).
  • a binder material can be added to the fleece material after it has been formed.
  • the binder material is in the form of a liquid coating.
  • a binding powder can be applied to the fleece material.
  • powdered polyethylene can be used as a binder material.
  • the liquid or powder coating can be applied, for example, between layers of fibers when cross-laying, air laying, or as an after treatment. A short exposure in an oven is sufficient to melt and fuse the binder material.
  • the means of producing the nonwoven web can vary.
  • Web formation can be accomplished by any means known in the art.
  • Web formation will typically involve a carding step, which involves deposition of the fibers onto a surface followed by aligning/blending the fibers in a machine direction. Thereafter, the fibrous web is typically subjected to some type of bonding/entanglement including, but not limited to, thermal fusion or bonding, mechanical entanglement, chemical adhesive, or a combination thereof.
  • the fibrous web is bonded thermally using a calendar (which can provide flat or point bonding), steam jet bonding, or a thru-air oven. Additional bonding methods include ultrasonic bonding and crimping.
  • needle punching is utilized, wherein needles are used to provide physical entanglement between fibers.
  • the web is entangled using hydroentanglement, which is a process used to entangle and bond fibers using hydrodynamic forces.
  • a binder material can be applied to the fibers of the fibrous web before laying the fibrous web, during formation of the fibrous web, and/or after the fibrous web has been bonded to form a fleece material. After forming the fleece material, heat can be applied to the fleece material in order to activate/at least partially melt the binder material to further bond the fleece material and thereby further enhance the mechanical integrity of the fleece material.
  • Methods for forming a nonwoven web comprising natural and synthetic fibers may include drylaid, airlaid and wetlaid methods.
  • the nonwoven fabric can be formed using a spunlaid or spunmelt process, which includes both spunbond and meltblown processes, wherein such processes are understood to typically entail melting, extruding, collecting and bonding thermoplastic polymer materials to form a fibrous nonwoven web.
  • the technique of meltblowing is known in the art and is discussed in various patents, for example, U.S. Pat. Nos.
  • the nonwoven web is made by providing a dry laid or a spun laid web of fibers, and then needle punching the web to bond the dry laid or spun laid web.
  • the needle punched fleece material is produced when barbed needles are pushed through the fibrous web, forcing some fibers upwards or downwards through the web by the barbed needles.
  • the fibers punched through the web remain at their new position once the needles are withdrawn. This needling action interlocks fibers and holds the structure together by inter fiber friction forces caused by compression of the web, thereby bonding the web.
  • the web is converted into a nonwoven fabric.
  • the nonwoven web is made by a fleece carding process with point bonding.
  • the point bonding (e.g., using a calendar) should be limited to a relatively small portion of the surface area of the nonwoven web to maintain good porosity in the web for migration of water-soluble components through the web during oral use.
  • the point bonding is limited to less than about 60% of the surface area of the nonwoven web (or resulting pouch), such as less than about 50%, less than about 30%, or less than about 20% (e.g., about 1% to about 50%, about 5% to about 40%, or about 10% to about 30%).
  • An advantage of point bonding is the ability to control the porosity, flexibility and fabric strength.
  • the nonwoven web can be subjected to hydroentangling.
  • hydroentangled or “spunlaced” as applied to a nonwoven fabric herein defines a web subjected to impingement by a curtain of high speed, fine waterjets, typically emanating from a nozzle jet strip accommodated in a pressure vessel often referred to as a manifold or an injector.
  • This hydroentangled fabric can be characterized by reoriented, twisted, turned and entangled fibers.
  • the fibers can be hydroentangled by exposing the nonwoven web to water pressure from one or more hydroentangling manifolds at a water pressure in the range of about 10 bar to about 1000 bar.
  • spunlace technology in certain embodiments, will have less impact on porosity of the web and, thus, may enhance flavor transfer through the nonwoven pouch material.
  • the nonwoven web can be subjected to a second bonding method in order to reduce elongation of the web during processing.
  • nonwoven webs of the present disclosure can exhibit significant elongation during high speed processing on pouching equipment. Too much elongation of the nonwoven web can cause the web to shrink during processing, such that the final product is not sized appropriately. As such, it can be necessary to modify process equipment to fit a wider roll of fleece, for example, to compensate for any shrinkage in the final product due to elongation.
  • the nonwoven web can be point bonded after the first bonding (e.g., hydroentangling) is completed.
  • a second bonding process can increase the tensile strength of the nonwoven web and reduce elongation characteristics.
  • a point bonding process can bond a nonwoven web by partially or completely melting the web (e.g., the heat sealable binder material) at discrete points.
  • the nonwoven web can be subjected to ultrasonic bonding after initial bonding of the web. Any ultrasonic bonding system for nonwoven materials known in the art can be used to ultrasonically bond the nonwoven web. See, for example, the apparatuses and devices disclosed in U.S.
  • the nonwoven web can be subjected to point bonding via embossed and/or engraved calendar rolls, which are typically heated. See, e.g., the point bonding methods incorporating the use of very high calendar pressures and embossing techniques discussed in U.S. Pat. Publ. No. 2008/0249492 to Schmidt, herein incorporated by reference in its entirety.
  • the point bonding process is typically limited to less than about 60% of the surface area of the nonwoven web as noted above.
  • the processing techniques used to blend, entangle and bond the nonwoven web can also impart a desired texture to the fibrous nonwoven web material.
  • a desired texture e.g. a desired pattern
  • This textured pattern can include product identifying information.
  • the product identifying information is selected from the group consisting of product brand, a company name, a corporate logo, a corporate brand, a marketing message, product strength, active ingredient, product manufacture date, product expiration date, product flavor, product release profde, weight, product code (e.g., batch code), other product differentiating markings, and combinations thereof.
  • US Publication No. 2012/0055493 to Novak, III et al. incorporated by reference in its entirety, relates to an apparatus and process for providing pouch material formed into a tube for use in the manufacture of smokeless tobacco products.
  • the pouch material can include a binder material according to the present disclosure (e.g. , a binder material comprising an aliphatic polyester).
  • Similar apparatuses that incorporate equipment for supplying a continuous supply of a pouch material e.g., a pouch processing unit adapted to supply a pouch material to a continuous tube forming unit for forming a continuous tubular member from the pouch material
  • a pouch processing unit adapted to supply a pouch material to a continuous tube forming unit for forming a continuous tubular member from the pouch material
  • the apparatus further includes equipment for supplying pouched material to the continuous tubular member such that, when the continuous tubular member is subdivided and sealed into discrete pouch portions, each pouch portion includes a charge of a composition adapted for oral use.
  • Representative equipment for supplying the fdler material is disclosed, for example, in U.S. Patent Application Publication No. US 2010/0018539 to Brinkley, which is incorporated herein by reference in its entirety.
  • the apparatus may include a subdividing unit for subdividing the continuous tubular member into individual pouch portions and, once subdivided into the individual pouch portions, may also include a sealing unit for sealing at least one of the ends of each pouch portion.
  • the continuous tubular member may be sealed into individual pouch portions with a sealing unit and then, once the individual pouch portions are sealed, the continuous tubular member may be subdivided into discrete individual pouch portions by a subdividing unit subdividing the continuous tubular member between the sealed ends of serially-disposed pouch portions.
  • sealing (closing) of the individual pouch portions of the continuous tubular member may occur substantially concurrently with the subdivision thereof, using a closing and dividing unit.
  • an apparatus similar to that described in U.S. Publication No. 2012/0055493 can be configured to removably receive a first bobbin on an unwind spindle assembly, the first bobbin having a continuous length of a material, such as a pouch material, wound thereon.
  • the pouch material can be routed from the first bobbin to a forming unit configured to form a continuous supply of the pouch material into a continuous tubular member defining a longitudinal axis.
  • a forming unit configured to form a continuous supply of the pouch material into a continuous tubular member defining a longitudinal axis.
  • the pouch material can be directed around an arrangement of roller members, otherwise referred to herein as a dancer assembly.
  • a forming unit can be configured to cooperate with the first bobbin and the dancer assembly to take up slack in the pouch material and to maintain a certain amount of longitudinal tension on the pouch material as the pouch material is unwound from the first bobbin and fed to the forming unit, for example, by a drive system.
  • the pouch material can be supported, routed, and/or guided by a suitably aligned series of any number of, for example, idler rollers, guideposts, air bars, turning bars, guides, tracks, tunnels, or the like, for directing the pouch material along the desired path.
  • Typical bobbins used by conventional automated pouch making apparatuses often contain a continuous strip of pouch material of which the length may vary.
  • the apparatus described herein can be configured so as to handle bobbins of that type and size.
  • the forming unit can include one or more roller members configured to direct the pouch material about a hollow shaft such that the continuous supply of the pouch material can be formed into a continuous tubular member.
  • the forming unit can include a sealing device configured to seal, fix, or otherwise engage lateral edges of the pouch material to form a longitudinally-extending seam, thereby forming a longitudinally-extending continuous tubular member.
  • an insertion unit can be configured to introduce charges of the composition adapted for oral use into the continuous tubular member through the hollow shaft. The insertion unit may be directly or indirectly engaged with the hollow shaft.
  • a leading edge or end (also referred to as a laterally-extending seam) of the continuous tubular member can be closed/sealed such that a charge of composition adapted for oral use inserted by the insertion unit, is contained within the continuous tubular member proximate to the leading end.
  • the leading end can be closed/sealed via a closing and dividing unit configured to close/seal a first portion of the continuous tubular member to form the closed leading end of a pouch member portion.
  • the closing and dividing unit can also be configured to form a closed trailing edge or end of a previous pouch member portion.
  • the closing and dividing unit can also be configured to close a second portion of the continuous tubular member to form the closed trailing end of the pouch member portion.
  • the closing and dividing unit can close the ends, by heat-sealing, or other suitable sealing mechanism.
  • the closing and dividing unit can be configured to divide the continuous tubular member, between the closed trailing end and the closed leading end of serially-disposed pouch member portions, along the longitudinal axis of the continuous tubular member, and into a plurality of discrete pouch member portions such that each discrete pouch member portion includes a portion of the oral composition from the insertion unit.
  • the closing and dividing unit can include a blade, heated wire, or other cutting arrangement for severing the continuous tubular member into discrete pouch member portions.
  • the closing and dividing unit can include first and second arm members configured to interact to close and divide the continuous tubular member.
  • a charge of the composition adapted for oral use i.e., an amount suitable for an individual pouch member portion
  • the discrete individual pouch member portion can be formed by closing the trailing end and severing the closed pouch member portion from the continuous tubular member such that an individual pouched product is formed.
  • each pouch may vary.
  • the weight of the mixture within each pouch is at least about 50 mg, for example, from about 50 mg to about 2 grams, from about 100 mg to about 1.5 grams, or from about 200 mg to about 700 mg.
  • the dry weight of the material within each pouch is at least about 50 mg to about 150 mg.
  • the dry weight of the material within each pouch preferably does not exceed about 300 mg to about 500 mg.
  • each pouch/container may have disposed therein a flavor agent member, as described in greater detail in US Pat. No. 7,861,728 to Holton, Jr. et al., which is incorporated herein by reference.
  • At least one flavored strip, piece or sheet of flavored water dispersible or water soluble material may be disposed within each pouch along with or without at least one capsule.
  • flavored water dispersible or water soluble material e.g., a breath-freshening edible film type of material
  • Such strips or sheets may be folded or crumpled in order to be readily incorporated within the pouch. See, for example, the types of materials and technologies set forth in US Pat. Nos. 6,887,307 to Scott et al. and 6,923,981 to Ueung et al.; and The EFSA Journal (2004) 85, 1-32; which are incorporated herein by reference.
  • the nonwoven web can be sufficiently tacky so as to create issues with high-speed pouching equipment. Therefore, in certain embodiments, a Teflon coating, or similar material, can be applied to one or more surfaces of the pouching equipment that touch the nonwoven web such as, for example, rollers, cutting instruments, and heat sealing devices in order to reduce and/or alleviate any problems associated with the pouch material sticking to the pouching equipment during processing.
  • the pouched products can further include product identifying information printed or dyed on the outer water-permeable pouch or imprinted (e.g., embossed, debossed, or otherwise pressed) on the outer water-permeable pouch, such as described in U.S. Pat. Appl. Pub. No. 2014/0255452 to Reddick et al., filed March 11, 2013, which is incorporated by reference herein.
  • flavorants can also be incorporated into the nonwoven web if desired, such as by coating or printing an edible flavorant ink onto the nonwoven web. See, e.g., U.S. Pat. Appl. Pub. Nos. 2012/0085360 to Kawata et al. and 2012/0103353 to Sebastian et al., each of which is herein incorporated by reference.
  • a pouched product as described herein can be packaged within any suitable inner packaging material and/or outer container. See also, for example, the various types of containers for smokeless types of products that are set forth in US Pat. Nos. 7,014,039 to Henson et al.; 7,537,110 to Kutsch et al.; 7,584,843 to Kutsch et al.; 8,397,945 to Gelardi et al., D592,956 to Thiellier; D594,154 to Patel et al.; and D625,178 to Bailey et al.; US Pat. Pub. Nos.
  • Products of the present disclosure configured for oral use may be packaged and stored in any suitable packaging in much the same manner that conventional types of smokeless tobacco products are packaged and stored.
  • a plurality of packets or pouches may be contained in a cylindrical container.
  • the storage period of the product after preparation may vary.
  • “storage period” refers to the period of time after the preparation of the disclosed product.
  • one or more of the characteristics of the products disclosed herein e.g., retention of whiteness, lack of color change, retention of volatile flavor components
  • the storage period i.e., the time period after preparation
  • the storage period is from about about 1 day, about 2 days, or about 3 days, to about 1 week, or from about 1 week to about 2 weeks, from about 2 weeks to about 1 month, from about 1 month to about 2 months, from about 2 months to about 3 months, from about 3 months to about 4 months, or from about 4 months to about 5 months.
  • the storage period is any number of days between about 1 and about 150.
  • the storage period may be longer than 5 months, for example, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, or about 12 months.
  • nonwoven pouched products were produced, containing a mixture comprising one or more rupturable capsules as described herein, according to the following Examples.
  • Example 1A-1D Various pouched products (Examples 1A-1D) were prepared, each comprising a mixture within a pouch.
  • the composition of the mixture within the pouch is provided in Tables 1-4 below (with all values provided in weight percentages based on the total weight of the mixture).
  • the components were combined and a given amount of the mixture (e.g., about 360-365 mg) was placed within a non-woven fleece pouch (with dimensions 38 x 12, fleece weight about 38 mg).
  • a single capsule (21.5 mg) was added to each pouch before sealing.
  • the capsule of each example comprises a menthol payload surrounded by a carrageenan capsule wall.
  • the pouch was not sprayed with additional water, i.e., the total final pouch weight for each Example was about 421.5 mg.
  • the nicotine content of the final pouch was about 1.5% and the pH of each pouched product was 8.6-9.
  • Table 1A Example 1A
  • Example 1A The oven volatiles of Example 1A were 2-10%, and the final pack moisture was 3-8%.
  • Example IB The oven volatiles of Example IB were 9-19%, and the final pack moisture was 3-8%.
  • Example 1C (nicotine, propylene glycol, water, and flavorant in capsule)
  • Example ID The oven volatiles of Example 1C were 10-19%, and the final pack moisture was 3-8%. Table 4: Example ID
  • Example ID The oven volatiles of Example ID were 19-29%, and the final pack moisture was 3-8%.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions orales et des produits en sachet contenant une ou plusieurs capsules, lesquelles compositions et produits peuvent avoir une teneur en eau inférieure à environ 20 % en poids, certains de ces produits comprenant une poche externe perméable à l'eau définissant une cavité contenant une composition comprenant la ou les capsules, et contenant en outre un ou plusieurs composants solubles dans l'eau pouvant être libérés à travers la poche perméable à l'eau.
PCT/IB2023/060370 2022-10-14 2023-10-13 Produits en sachet contenant des capsules WO2024079722A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263416309P 2022-10-14 2022-10-14
US63/416,309 2022-10-14

Publications (1)

Publication Number Publication Date
WO2024079722A1 true WO2024079722A1 (fr) 2024-04-18

Family

ID=88505156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/060370 WO2024079722A1 (fr) 2022-10-14 2023-10-13 Produits en sachet contenant des capsules

Country Status (1)

Country Link
WO (1) WO2024079722A1 (fr)

Citations (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US787611A (en) 1903-06-17 1905-04-18 American Cigar Company Treating tobacco.
US1086306A (en) 1912-11-11 1914-02-03 Theodor Oelenheinz Process of bleaching tobacco-leaves.
US1437095A (en) 1920-06-01 1922-11-28 August Wasmuth Process of bleaching tobacco
US1757477A (en) 1927-07-11 1930-05-06 Rosenhoch Samuel Process and device for ozonizing tobacco
US2033909A (en) 1934-12-19 1936-03-17 Niacet Chemicals Corp Manufacture of calcium levulinate
US2122421A (en) 1937-07-30 1938-07-05 Du Pont Tobacco treatment
US2148147A (en) 1933-12-30 1939-02-21 Degussa Process for bleaching tobacco
US2170107A (en) 1935-01-28 1939-08-22 Degussa Process for bleaching tobacco
US2274649A (en) 1935-01-28 1942-03-03 Degussa Process for bleaching tobacco
US2770239A (en) 1952-02-04 1956-11-13 Prats Jose Romero Process of treating tobacco
US2822306A (en) 1955-07-01 1958-02-04 Plate Gmbh Dr Aromatic and pleasant tasting de-nicotinized tobacco and method of producing same
US3338992A (en) 1959-12-15 1967-08-29 Du Pont Process for forming non-woven filamentary structures from fiber-forming synthetic organic polymers
US3339558A (en) 1966-10-28 1967-09-05 Haskett Barry F Smoking article and filter therefor containing vitamin a
US3341394A (en) 1966-12-21 1967-09-12 Du Pont Sheets of randomly distributed continuous filaments
US3390686A (en) 1965-12-21 1968-07-02 American Tobacco Co Tobacco smoke filter element
US3502763A (en) 1962-02-03 1970-03-24 Freudenberg Carl Kg Process of producing non-woven fabric fleece
US3542615A (en) 1967-06-16 1970-11-24 Monsanto Co Process for producing a nylon non-woven fabric
US3550598A (en) 1967-08-15 1970-12-29 James H Mcglumphy Reconstituted tobacco containing adherent encapsulated flavors and other matter
US3612065A (en) 1970-03-09 1971-10-12 Creative Enterprises Inc Method of puffing tobacco and reducing nicotine content thereof
US3685521A (en) 1970-06-16 1972-08-22 H 2 O Filter Corp The Cigarette holder containing actuated carbon and frangible capsule
US3692618A (en) 1969-10-08 1972-09-19 Metallgesellschaft Ag Continuous filament nonwoven web
US3802817A (en) 1969-10-01 1974-04-09 Asahi Chemical Ind Apparatus for producing non-woven fleeces
US3849241A (en) 1968-12-23 1974-11-19 Exxon Research Engineering Co Non-woven mats by melt blowing
US3851653A (en) 1972-10-11 1974-12-03 Rosen Enterprises Inc Method of puffing tobacco and reducing nicotine content thereof
US3889689A (en) 1971-12-20 1975-06-17 Rosen Enterprise Inc Method of treating tobacco with catalase and hydrogen peroxide
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3916914A (en) 1972-06-06 1975-11-04 Brown & Williamson Tobacco Smoking articles
US3943945A (en) 1971-09-20 1976-03-16 Rosen Enterprises, Inc. Process for preparation of reconstituted tobacco sheet
US3943940A (en) 1974-09-13 1976-03-16 Isao Minami Method of removing nicotine in smoking and a smoking filter to be used therefor
US3972759A (en) 1972-06-29 1976-08-03 Exxon Research And Engineering Company Battery separators made from polymeric fibers
US3987185A (en) 1973-11-12 1976-10-19 Richardson-Merrell Inc. Method of treatment using 1-oxo-1h-2-benzopyran-3-carboxylic acid derivatives
US4143666A (en) 1975-08-15 1979-03-13 Philip Morris Incorporated Smoking material
US4144895A (en) 1974-03-08 1979-03-20 Amf Incorporated Solvent extraction process
US4148325A (en) 1975-08-18 1979-04-10 British-American Tobacco Company Limited Treatment of tobacco
US4150677A (en) 1977-01-24 1979-04-24 Philip Morris Incorporated Treatment of tobacco
US4153063A (en) 1970-09-02 1979-05-08 Studiengesellschaft Kohle Mbh Process for the extraction of nicotine from tobacco
US4194514A (en) 1976-09-27 1980-03-25 Stauffer Chemical Company Removal of radioactive lead and polonium from tobacco
US4237274A (en) 1978-02-24 1980-12-02 Snia Viscosa Societa' Nazionale Industria Applicazioni Viscosa S.P.A. Process for the preparation of solutions of cellulose derivatives which can be coagulated and spun to form regenerated cellulose _bodies
US4252766A (en) 1978-07-27 1981-02-24 Snia Viscosa Societa Nazionale Industria Applicazioni Viscosa S.P.A. Process for the preparation of formed bodies of regenerated cellulose from solutions of cellulose derivatives in dimethylsulphoxide
US4268666A (en) 1978-04-03 1981-05-19 Snia Viscosa Societa Nazionale Industria Applicazioni Viscosa S.P.A. Process for the dissolution of cellulose in organic solvents, solutions obtained by said process, and process for the production of formed bodies of regenerated cellulose from said solutions
US4267847A (en) 1978-05-12 1981-05-19 British-American Tobacco Company Limited Tobacco additives
US4289147A (en) 1979-11-15 1981-09-15 Leaf Proteins, Inc. Process for obtaining deproteinized tobacco freed of nicotine and green pigment, for use as a smoking product
US4340073A (en) 1974-02-12 1982-07-20 Philip Morris, Incorporated Expanding tobacco
US4340563A (en) 1980-05-05 1982-07-20 Kimberly-Clark Corporation Method for forming nonwoven webs
US4351346A (en) 1980-03-08 1982-09-28 B.A.T. Cigaretten-Fabriken Gmbh Process for the preparation of aromatic substances
US4359059A (en) 1980-03-08 1982-11-16 B.A.T. Cigaretten-Fabriken Gmbh Process for the preparation of aromatic substances
US4366823A (en) 1981-06-25 1983-01-04 Philip Morris, Incorporated Process for expanding tobacco
US4366824A (en) 1981-06-25 1983-01-04 Philip Morris Incorporated Process for expanding tobacco
US4388256A (en) 1978-11-24 1983-06-14 Masamichi Ishida Process for manufacturing regenerated cellulose hollow fiber
US4388933A (en) 1981-06-25 1983-06-21 Philip Morris, Inc. Tobacco stem treatment and expanded tobacco product
US4506682A (en) 1981-12-07 1985-03-26 Mueller Adam Clear tobacco aroma oil, a process for obtaining it from a tobacco extract, and its use
US4535028A (en) 1981-10-01 1985-08-13 Asahi Kasei Kogyo Kabushiki Kaisha Hollow fiber of cuprammonium regenerated cellulose and process for producing the same
US4589428A (en) 1980-02-21 1986-05-20 Philip Morris Incorporated Tobacco treatment
US4605016A (en) 1983-07-21 1986-08-12 Japan Tobacco, Inc. Process for preparing tobacco flavoring formulations
US4622259A (en) 1985-08-08 1986-11-11 Surgikos, Inc. Nonwoven medical fabric
US4641667A (en) 1983-12-09 1987-02-10 B.A.T. Cigarettenfabriken Gmbh Process of preparing nicotine N'-oxide and smoking products containing it
US4660577A (en) 1982-08-20 1987-04-28 R.J. Reynolds Tobacco Company Dry pre-mix for moist snuff
US4716911A (en) 1986-04-08 1988-01-05 Genencor, Inc. Method for protein removal from tobacco
US4725440A (en) 1982-07-02 1988-02-16 E. R. Squibb & Sons, Inc. Antifungal pastille formulation and method
US4727889A (en) 1986-12-22 1988-03-01 R. J. Reynolds Tobacco Company Tobacco processing
US4887618A (en) 1988-05-19 1989-12-19 R. J. Reynolds Tobacco Company Tobacco processing
US4889144A (en) 1987-05-29 1989-12-26 Japan Tobacco Inc. Filter for tobacco smoking
US4941484A (en) 1989-05-30 1990-07-17 R. J. Reynolds Tobacco Company Tobacco processing
US4967771A (en) 1988-12-07 1990-11-06 R. J. Reynolds Tobacco Company Process for extracting tobacco
US4986286A (en) 1989-05-02 1991-01-22 R. J. Reynolds Tobacco Company Tobacco treatment process
US5004595A (en) 1986-12-23 1991-04-02 Warner-Lambert Company Multiple encapsulated flavor delivery system and method of preparation
US5005593A (en) 1988-01-27 1991-04-09 R. J. Reynolds Tobacco Company Process for providing tobacco extracts
US5018540A (en) 1986-12-29 1991-05-28 Philip Morris Incorporated Process for removal of basic materials
US5060669A (en) 1989-12-18 1991-10-29 R. J. Reynolds Tobacco Company Tobacco treatment process
US5065775A (en) 1990-02-23 1991-11-19 R. J. Reynolds Tobacco Company Tobacco processing
US5074319A (en) 1990-04-19 1991-12-24 R. J. Reynolds Tobacco Company Tobacco extraction process
US5099862A (en) 1990-04-05 1992-03-31 R. J. Reynolds Tobacco Company Tobacco extraction process
US5121757A (en) 1989-12-18 1992-06-16 R. J. Reynolds Tobacco Company Tobacco treatment process
US5131414A (en) 1990-02-23 1992-07-21 R. J. Reynolds Tobacco Company Tobacco processing
US5131415A (en) 1991-04-04 1992-07-21 R. J. Reynolds Tobacco Company Tobacco extraction process
US5148819A (en) 1991-08-15 1992-09-22 R. J. Reynolds Tobacco Company Process for extracting tobacco
US5197494A (en) 1991-06-04 1993-03-30 R.J. Reynolds Tobacco Company Tobacco extraction process
US5223185A (en) 1991-04-19 1993-06-29 Freund Industrial Co., Ltd. Method of manufacturing seamless capsules and apparatus therefor
US5230354A (en) 1991-09-03 1993-07-27 R. J. Reynolds Tobacco Company Tobacco processing
US5234008A (en) 1990-02-23 1993-08-10 R. J. Reynolds Tobacco Company Tobacco processing
US5243999A (en) 1991-09-03 1993-09-14 R. J. Reynolds Tobacco Company Tobacco processing
US5259403A (en) 1992-03-18 1993-11-09 R. J. Reynolds Tobacco Company Process and apparatus for expanding tobacco cut filler
US5301694A (en) 1991-11-12 1994-04-12 Philip Morris Incorporated Process for isolating plant extract fractions
US5318050A (en) 1991-06-04 1994-06-07 R. J. Reynolds Tobacco Company Tobacco treatment process
US5343879A (en) 1991-06-21 1994-09-06 R. J. Reynolds Tobacco Company Tobacco treatment process
US5360022A (en) 1991-07-22 1994-11-01 R. J. Reynolds Tobacco Company Tobacco processing
US5387093A (en) 1991-05-28 1995-02-07 Freund Inphachem Inc. Apparatus for manufacturing seamless capsules
US5387416A (en) 1993-07-23 1995-02-07 R. J. Reynolds Tobacco Company Tobacco composition
US5435325A (en) 1988-04-21 1995-07-25 R. J. Reynolds Tobacco Company Process for providing tobacco extracts using a solvent in a supercritical state
US5441689A (en) 1991-12-02 1995-08-15 Courtaulds Plc Process of making regenerated cellulose articles
US5445169A (en) 1992-08-17 1995-08-29 R. J. Reynolds Tobacco Company Process for providing a tobacco extract
US5539093A (en) 1994-06-16 1996-07-23 Fitzmaurice; Wayne P. DNA sequences encoding enzymes useful in carotenoid biosynthesis
WO1996031255A1 (fr) 1995-04-07 1996-10-10 George Giolvas Procede et appareil pour l'elimination des constituants nocifs des cigarettes et du tabac avant leur consommation
US5668295A (en) 1990-11-14 1997-09-16 Philip Morris Incorporated Protein involved in nicotine synthesis, DNA encoding, and use of sense and antisense DNAs corresponding thereto to affect nicotine content in transgenic tobacco cells and plants
US5690990A (en) 1994-03-04 1997-11-25 Arnhem, Inc. Process for encapsulating the flavor with colloid gel matrix
US5705624A (en) 1995-12-27 1998-01-06 Fitzmaurice; Wayne Paul DNA sequences encoding enzymes useful in phytoene biosynthesis
US5713376A (en) 1996-05-13 1998-02-03 Berger; Carl Non-addictive tobacco products
US5759599A (en) 1992-03-30 1998-06-02 Givaudan Roure Flavors Corporation Method of flavoring and mechanically processing foods with polymer encapsulated flavor oils
US5844119A (en) 1994-12-21 1998-12-01 The Salk Institute For Biological Studies Genetically modified plants having modulated flower development
US5882680A (en) 1995-12-07 1999-03-16 Freund Industrial Co., Ltd. Seamless capsule and method of manufacturing the same
US5908032A (en) 1996-08-09 1999-06-01 R.J. Reynolds Tobacco Company Method of and apparatus for expanding tobacco
US5997790A (en) 1995-11-20 1999-12-07 Michelin Recherche Et Technique S.A. Process for the preparation of regenerated cellulose filaments
US6039901A (en) 1997-01-31 2000-03-21 Givaudan Roure Flavors Corporation Enzymatically protein encapsulating oil particles by complex coacervation
US6045835A (en) 1997-10-08 2000-04-04 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
US6056992A (en) 1988-06-02 2000-05-02 Campbell Soup Company Encapsulated additives
US6077524A (en) 1994-05-06 2000-06-20 Bolder Arzneimittel Gmbh Gastric acid binding chewing pastilles
US6083527A (en) 1998-11-05 2000-07-04 Thistle; Robert Breath mint with tooth decay and halitosis prevention characteristics
US6106875A (en) 1997-10-08 2000-08-22 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6131584A (en) 1999-04-15 2000-10-17 Brown & Williamson Tobacco Corporation Tobacco treatment process
US6298859B1 (en) 1998-07-08 2001-10-09 Novozymes A/S Use of a phenol oxidizing enzyme in the treatment of tobacco
US6325859B1 (en) 1996-10-09 2001-12-04 Givaudan Roure (International) Sa Process for preparing beads as food or tobacco additive
US6482433B1 (en) 1999-06-30 2002-11-19 Givaudan Sa Encapsulation of active ingredients
US6510855B1 (en) 2000-03-03 2003-01-28 Brown & Williamson Tobacco Corporation Tobacco recovery system
WO2003009711A1 (fr) 2001-07-24 2003-02-06 Jinhee Kim Tabac a gout changeant
US6612429B2 (en) 2001-06-22 2003-09-02 Brown & Williamson Tobacco Corporation Flip open package with microencapsulated flavor release
US6631722B2 (en) 1993-09-30 2003-10-14 British-American Tobacco Company Limited Tobacco smoke filter elements
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US6719933B2 (en) 1999-12-20 2004-04-13 Chugai Seiyaku Kabushiki Kaisha Method for manufacturing seamless capsule
US6730832B1 (en) 2001-09-10 2004-05-04 Luis Mayan Dominguez High threonine producing lines of Nicotiana tobacum and methods for producing
US6772767B2 (en) 2002-09-09 2004-08-10 Brown & Williamson Tobacco Corporation Process for reducing nitrogen containing compounds and lignin in tobacco
US20040191322A1 (en) 2002-12-20 2004-09-30 Henri Hansson Physically and chemically stable nicotine-containing particulate material
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US6834654B2 (en) 2001-05-01 2004-12-28 Regent Court Technologies, Llc Smokeless tobacco product
US20040261807A1 (en) 2003-06-23 2004-12-30 Dube Michael Francis Filtered cigarette incorporating a breakable capsule
US6887307B1 (en) 1999-07-22 2005-05-03 Warner-Lambert Company, Llc Pullulan film compositions
WO2005041699A2 (fr) 2003-11-03 2005-05-12 U.S. Smokeless Tobacco Company Tabac sans fumee aromatise et procedes de fabrication de ce tabac
US6895974B2 (en) 1999-04-26 2005-05-24 R. J. Reynolds Tobacco Company Tobacco processing
US20050123601A1 (en) 2001-11-26 2005-06-09 Jean Mane Capsule for rapid solubilization and release of the content
WO2005063060A1 (fr) 2003-12-22 2005-07-14 U.S. Smokeless Tobacco Company Procede de traitement pour compositions de tabac ou de tabac a priser
US6923981B2 (en) 1998-09-25 2005-08-02 Warner-Lambert Company Fast dissolving orally consumable films
US6929814B2 (en) 1996-10-09 2005-08-16 Givaudan Sa Process for preparing beads as food additive and product thereof
US20050196437A1 (en) 2004-03-02 2005-09-08 Bednarz Christina A. Hard capsules
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
US6953040B2 (en) 2001-09-28 2005-10-11 U.S. Smokeless Tobacco Company Tobacco mint plant material product
US20050244521A1 (en) 2003-11-07 2005-11-03 Strickland James A Tobacco compositions
US20050249676A1 (en) 2004-05-04 2005-11-10 Robert Scott Pullulan capsules
US7014039B2 (en) 2003-06-19 2006-03-21 R.J. Reynolds Tobacco Company Sliding shell package for smoking articles
US7025066B2 (en) 2002-10-31 2006-04-11 Jerry Wayne Lawson Method of reducing the sucrose ester concentration of a tobacco mixture
US7032601B2 (en) 2001-09-28 2006-04-25 U.S. Smokeless Tobacco Company Encapsulated materials
US20060130961A1 (en) 2004-12-17 2006-06-22 Byrne Thomas T Method and apparatus for splicing a web material
US20060144412A1 (en) 2004-12-30 2006-07-06 Philip Morris Usa Inc. Encapsulated additives and methods of making encapsulated additives
US20060174901A1 (en) 2005-02-04 2006-08-10 Philip Morris Usa Inc. Flavor capsule for enhanced flavor delivery in cigarettes
US20060210488A1 (en) 2005-03-19 2006-09-21 Jakubowski Henryk P Teeth whitening candy with tartar removal and breath freshening properties
US7115085B2 (en) 2003-09-12 2006-10-03 R.J. Reynolds Tobacco Company Method and apparatus for incorporating objects into cigarette filters
US20060228308A1 (en) 2004-02-26 2006-10-12 Cummins Barry W Oral health care drink and method for reducing malodors
US20060236434A1 (en) 2000-08-30 2006-10-19 North Carolina State University Methods and compositions for tobacco plants with reduced nicotine
WO2006136199A1 (fr) 2005-06-21 2006-12-28 V.Mane Fils Article pour fumeur contenant une capsule frangible, capsule frangible et procede de fabrication associe
WO2006136197A1 (fr) 2005-06-21 2006-12-28 V. Mane Fils Produit a fumer comprenant une capsule cassante, capsule cassante et procede de fabrication de cette capsule
US20070012327A1 (en) 2005-05-03 2007-01-18 Philip Morris Usa Inc. Cigarettes and filter subassemblies with squeezable flavor capsule and methods of manufacture
WO2007010407A2 (fr) 2005-06-21 2007-01-25 V. Mane Fils Dispositif pour fumeur incorporant une capsule frangible, capsule frangible et procede de fabrication de ladite capsule
US20070062549A1 (en) 2005-09-22 2007-03-22 Holton Darrell E Jr Smokeless tobacco composition
US20070068540A1 (en) 2005-09-23 2007-03-29 Thomas Timothy F Equipment for insertion of objects into smoking articles
WO2007037962A1 (fr) 2005-09-22 2007-04-05 R.J. Reynolds Tobacco Company Composition de tabac qui ne se fume pas
US7208659B2 (en) 2001-05-02 2007-04-24 Conopco Inc. Process for increasing the flavonoid content of a plant and plants obtainable thereby
US20070095357A1 (en) 2005-11-01 2007-05-03 Philip Morris Usa Inc. Smoking article with manually releasable odorant
WO2007060543A2 (fr) 2005-08-15 2007-05-31 Philip Morris Products S.A. Dispositif de liberation de liquide destine a un article pour fumeur
US7230160B2 (en) 2001-03-08 2007-06-12 Michigan State University Lipid metabolism regulators in plants
WO2007104573A2 (fr) 2006-03-16 2007-09-20 Niconovum Ab Composition améliorée de tabac à priser
US20080029110A1 (en) * 2006-02-10 2008-02-07 R. J. Reynolds Tobacco Company Smokeless Tobacco Composition
US7337782B2 (en) 2004-08-18 2008-03-04 R.J. Reynolds Tobacco Company Process to remove protein and other biomolecules from tobacco extract or slurry
US20080173317A1 (en) 2006-08-01 2008-07-24 John Howard Robinson Smokeless tobacco
US20080196730A1 (en) 2004-07-02 2008-08-21 Radi Medical Systems Ab Smokeless Tobacco Product
WO2008103935A2 (fr) 2007-02-23 2008-08-28 U.S. Smokeless Tobacco Company Nouvelles compositions de tabac et leurs procédés de fabrication
US20080305216A1 (en) 2007-06-08 2008-12-11 Philip Morris Usa Inc. Capsule clusters for oral consumption
US20080302377A1 (en) 2007-06-05 2008-12-11 Michail Kassymovich Nauryzbaev Method for extraction of nicotine from tobacco raw material
US20090014450A1 (en) 2003-08-18 2009-01-15 Gustavus Ab Snuff-box lid
US20090014343A1 (en) 2007-05-07 2009-01-15 Philip Morris Usa Inc. Pocket-size hybrid container for consumer items
USD592956S1 (en) 2008-02-08 2009-05-26 Philip Morris Usa Inc. Container
US7537110B2 (en) 2005-06-02 2009-05-26 Philip Morris Usa Inc. Container for consumer article
USD594154S1 (en) 2007-11-13 2009-06-09 R.J. Reynolds Tobacco Company Container with bottom compartment
US7556047B2 (en) 2003-03-20 2009-07-07 R.J. Reynolds Tobacco Company Method of expanding tobacco using steam
US7584843B2 (en) 2005-07-18 2009-09-08 Philip Morris Usa Inc. Pocket-size hand-held container for consumer items
US20090223989A1 (en) 2008-03-04 2009-09-10 R.J. Reynolds Tobacco Company Dispensing Container
US20090230003A1 (en) 2008-02-08 2009-09-17 Philip Morris Usa Inc. Pocket-sized container
US20090250360A1 (en) 2007-11-30 2009-10-08 Philip Morris Usa Inc. Pocket-size container for consumer items
US20090266837A1 (en) 2008-04-25 2009-10-29 R. J. Reynolds Tobacco Company Dispensing Container
US20090293889A1 (en) 2007-11-28 2009-12-03 Philip Morris Usa Inc. Smokeless compressed tobacco product for oral consumption
US7650892B1 (en) 2004-09-03 2010-01-26 Rosswil Llc Ltd. Methods for hindering formation of tobacco-specific nitrosamines
US20100018539A1 (en) 2008-07-28 2010-01-28 Paul Andrew Brinkley Smokeless tobacco products and processes
US20100084424A1 (en) 2006-12-12 2010-04-08 John Gelardi Container with pivoting cover
US20100101588A1 (en) 2007-03-20 2010-04-29 Azionaria Costruzioni Macchine Automatiche A.C.M.A S.P.A. Machine for manufacturing pouches of cohesionless material
US20100133140A1 (en) 2008-12-01 2010-06-03 Bailey Ryan A Dual cavity sliding dispenser
US7798153B2 (en) 2004-08-23 2010-09-21 Us Smokeless Tobacco Co. Nicotiana Kawakamii smokeless tobacco
USD625178S1 (en) 2009-04-16 2010-10-12 R.J. Reynolds Tobacco Company, Inc. Container with hinged insert
US20100264157A1 (en) 2009-04-16 2010-10-21 R.J. Reynolds Tobacco Company Dispensing container for metered dispensing of product
US7819124B2 (en) 2006-01-31 2010-10-26 U.S. Smokeless Tobacco Company Tobacco articles and methods
US20100291245A1 (en) 2008-12-08 2010-11-18 Philip Morris Usa Inc. Soft, chewable and orally dissolvable and/or disintegrable products
WO2010132444A2 (fr) 2009-05-11 2010-11-18 U.S. Smokeless Tobacco Company Llc Procédé et dispositif pour aromatiser du tabac sans fumée
US7861728B2 (en) 2006-02-10 2011-01-04 R.J. Reynolds Tobacco Company Smokeless tobacco composition having an outer and inner pouch
US20110139164A1 (en) 2009-12-15 2011-06-16 R. J. Reynolds Tobacco Company Tobacco Product And Method For Manufacture
US20110168712A1 (en) 2010-01-12 2011-07-14 R.J. Reynolds Tobacco Company Dispensing container
US20110247640A1 (en) 2010-04-08 2011-10-13 R. J. Reynolds Tobacco Company Smokeless Tobacco Composition Comprising Tobacco-Derived Material and Non-Tobacco Plant Material
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8061362B2 (en) 2007-07-23 2011-11-22 R. J. Reynolds Tobacco Company Smokeless tobacco composition
US8096339B2 (en) 2008-03-27 2012-01-17 Herrmann Ultraschalltechnik Gmbh & Co. Kg Ultrasonic welding tool with fluid drive
US20120037175A1 (en) 2010-08-11 2012-02-16 R.J. Reynolds Tobacco Company Meltable smokeless tobacco composition
US20120055493A1 (en) 2010-09-02 2012-03-08 R.J. Reynolds Tobacco Company Apparatus for manufacturing a smokeless tobacco product incorporating an object, and associated method
US20120055494A1 (en) 2010-09-07 2012-03-08 Rj Reynolds Tobacco Company Smokeless Tobacco Product Comprising Effervescent Composition
US20120067361A1 (en) 2009-04-03 2012-03-22 X-International Aps Plant fiber product and method for its manufacture
US20120085360A1 (en) 2009-06-16 2012-04-12 Norio Kawata Oral tobacco product
US20120103353A1 (en) 2010-11-01 2012-05-03 Sebastian Andries D Smokeless tobacco products
US8177938B2 (en) 2007-01-19 2012-05-15 Georgia-Pacific Consumer Products Lp Method of making regenerated cellulose microfibers and absorbent products incorporating same
US8186360B2 (en) 2007-04-04 2012-05-29 R.J. Reynolds Tobacco Company Cigarette comprising dark air-cured tobacco
US20120138073A1 (en) 2010-12-01 2012-06-07 Rj Reynolds Tobacco Company Smokeless tobacco pastille and injection molding process for forming smokeless tobacco products
US20120138074A1 (en) 2010-12-01 2012-06-07 Rj Reynolds Tobacco Company Smokeless tobacco pastille and moulding process for forming smokeless tobacco products
US8397945B2 (en) 2010-02-23 2013-03-19 R.J. Reynolds Tobacco Company Dispensing container
US20130074855A1 (en) 2011-09-22 2013-03-28 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130074856A1 (en) 2011-09-22 2013-03-28 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US8434496B2 (en) 2009-06-02 2013-05-07 R. J. Reynolds Tobacco Company Thermal treatment process for tobacco materials
US20130152953A1 (en) 2011-12-14 2013-06-20 R. J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
WO2013122948A1 (fr) 2012-02-13 2013-08-22 R. J. Reynolds Tobacco Company Composition de tabac blanchi
US8557071B2 (en) 2009-04-27 2013-10-15 Herrmann Ultraschalltechnik Gmbh & Co. Kg Ultrasound welding device and method for welding material webs
US20130274296A1 (en) 2012-04-17 2013-10-17 R.J. Reynolds Tobacco Company Remelted ingestible products
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US20140083438A1 (en) 2012-09-21 2014-03-27 R.J. Reynolds Tobacco Company Fibrous composite tobacco-containing materials
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US8944072B2 (en) 2009-06-02 2015-02-03 R.J. Reynolds Tobacco Company Thermal treatment process for tobacco materials
US20150068545A1 (en) 2013-09-09 2015-03-12 R.J. Reynolds Tobacco Company Smokeless tobacco composition incorporating a botanical material
US8991403B2 (en) 2009-06-02 2015-03-31 R.J. Reynolds Tobacco Company Thermal treatment process for tobacco materials
US20150101627A1 (en) 2013-10-16 2015-04-16 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
US20150230515A1 (en) 2014-02-14 2015-08-20 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
US20160000140A1 (en) 2014-07-02 2016-01-07 R.J. Reynolds Tobacco Company Oral pouch products
US20160073686A1 (en) 2014-09-12 2016-03-17 R.J. Reynolds Tobacco Company Tobacco-derived filter element
US20160073689A1 (en) 2014-09-12 2016-03-17 R.J. Reynolds Tobacco Company Nonwoven pouch comprising heat sealable binder fiber
US9339058B2 (en) 2012-04-19 2016-05-17 R. J. Reynolds Tobacco Company Method for producing microcrystalline cellulose from tobacco and related tobacco product
US20160157515A1 (en) * 2014-12-05 2016-06-09 R.J. Reynolds Tobacco Company Smokeless tobacco pouch
US20170020183A1 (en) 2014-04-04 2017-01-26 X-International Aps Tobacco Raw Material
US9950858B2 (en) 2015-01-16 2018-04-24 R.J. Reynolds Tobacco Company Tobacco-derived cellulose material and products formed thereof
WO2018083114A1 (fr) 2016-11-02 2018-05-11 Winnington Ab Substance de tabac défibré
WO2020128971A1 (fr) 2018-12-20 2020-06-25 R. J. Reynolds Tobacco Company Procédé de blanchiment de tabac
US20200331884A1 (en) 2017-12-22 2020-10-22 Siegfried Ag Preparation of racemic nicotine by reaction of ethyl nicotinate with n-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps
US10913962B2 (en) 2018-11-16 2021-02-09 Zanoprima Lifesciences Limited Process of making (S)-nicotine
WO2021048769A1 (fr) 2019-09-13 2021-03-18 Nicoventures Trading Limited Procédé de blanchiment de tabac
WO2021048768A1 (fr) 2019-09-11 2021-03-18 Nicoventures Trading Limited Procédé de blanchiment de tabac
WO2021048770A1 (fr) 2019-09-11 2021-03-18 Nicoventures Trading Limited Procédés alternatifs de blanchiment du tabac
WO2021058063A2 (fr) 2019-09-23 2021-04-01 Polysecure Gmbh Procédé de tri
US20210169121A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Liquid oral composition
US20210169792A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral compositions and methods of manufacture
US20210169122A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral foam composition
US20210169867A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Moist oral compositions
US20210169132A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral composition including gels
US20210177754A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Nanoemulsion for oral use
US20210177043A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product
US20210177038A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral products with active ingredient combinations
US20210186081A1 (en) 2019-12-09 2021-06-24 Nicoventures Trading Limited Pouched oral product with cannabinoid
US20210330590A1 (en) 2019-12-09 2021-10-28 Nicoventures Trading Limited Agents for oral composition
US20210378948A1 (en) 2020-06-08 2021-12-09 Nicoventures Trading Limited Effervescent oral composition
US20220071984A1 (en) 2019-09-11 2022-03-10 Nicoventures Trading Limited Oral product with nicotine and ion pairing agent
US20220160675A1 (en) 2020-11-25 2022-05-26 Nicoventures Trading Limited Oral cannabinoid product with lipid component

Patent Citations (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US787611A (en) 1903-06-17 1905-04-18 American Cigar Company Treating tobacco.
US1086306A (en) 1912-11-11 1914-02-03 Theodor Oelenheinz Process of bleaching tobacco-leaves.
US1437095A (en) 1920-06-01 1922-11-28 August Wasmuth Process of bleaching tobacco
US1757477A (en) 1927-07-11 1930-05-06 Rosenhoch Samuel Process and device for ozonizing tobacco
US2148147A (en) 1933-12-30 1939-02-21 Degussa Process for bleaching tobacco
US2033909A (en) 1934-12-19 1936-03-17 Niacet Chemicals Corp Manufacture of calcium levulinate
US2170107A (en) 1935-01-28 1939-08-22 Degussa Process for bleaching tobacco
US2274649A (en) 1935-01-28 1942-03-03 Degussa Process for bleaching tobacco
US2122421A (en) 1937-07-30 1938-07-05 Du Pont Tobacco treatment
US2770239A (en) 1952-02-04 1956-11-13 Prats Jose Romero Process of treating tobacco
US2822306A (en) 1955-07-01 1958-02-04 Plate Gmbh Dr Aromatic and pleasant tasting de-nicotinized tobacco and method of producing same
US3338992A (en) 1959-12-15 1967-08-29 Du Pont Process for forming non-woven filamentary structures from fiber-forming synthetic organic polymers
US3502763A (en) 1962-02-03 1970-03-24 Freudenberg Carl Kg Process of producing non-woven fabric fleece
US3390686A (en) 1965-12-21 1968-07-02 American Tobacco Co Tobacco smoke filter element
US3339558A (en) 1966-10-28 1967-09-05 Haskett Barry F Smoking article and filter therefor containing vitamin a
US3341394A (en) 1966-12-21 1967-09-12 Du Pont Sheets of randomly distributed continuous filaments
US3542615A (en) 1967-06-16 1970-11-24 Monsanto Co Process for producing a nylon non-woven fabric
US3550598A (en) 1967-08-15 1970-12-29 James H Mcglumphy Reconstituted tobacco containing adherent encapsulated flavors and other matter
US3849241A (en) 1968-12-23 1974-11-19 Exxon Research Engineering Co Non-woven mats by melt blowing
US3802817A (en) 1969-10-01 1974-04-09 Asahi Chemical Ind Apparatus for producing non-woven fleeces
US3692618A (en) 1969-10-08 1972-09-19 Metallgesellschaft Ag Continuous filament nonwoven web
US3612065A (en) 1970-03-09 1971-10-12 Creative Enterprises Inc Method of puffing tobacco and reducing nicotine content thereof
US3685521A (en) 1970-06-16 1972-08-22 H 2 O Filter Corp The Cigarette holder containing actuated carbon and frangible capsule
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US4153063A (en) 1970-09-02 1979-05-08 Studiengesellschaft Kohle Mbh Process for the extraction of nicotine from tobacco
US3943945A (en) 1971-09-20 1976-03-16 Rosen Enterprises, Inc. Process for preparation of reconstituted tobacco sheet
US3889689A (en) 1971-12-20 1975-06-17 Rosen Enterprise Inc Method of treating tobacco with catalase and hydrogen peroxide
US3916914A (en) 1972-06-06 1975-11-04 Brown & Williamson Tobacco Smoking articles
US3972759A (en) 1972-06-29 1976-08-03 Exxon Research And Engineering Company Battery separators made from polymeric fibers
US3851653A (en) 1972-10-11 1974-12-03 Rosen Enterprises Inc Method of puffing tobacco and reducing nicotine content thereof
US3987185A (en) 1973-11-12 1976-10-19 Richardson-Merrell Inc. Method of treatment using 1-oxo-1h-2-benzopyran-3-carboxylic acid derivatives
US4340073A (en) 1974-02-12 1982-07-20 Philip Morris, Incorporated Expanding tobacco
US4144895A (en) 1974-03-08 1979-03-20 Amf Incorporated Solvent extraction process
US3943940A (en) 1974-09-13 1976-03-16 Isao Minami Method of removing nicotine in smoking and a smoking filter to be used therefor
US4143666A (en) 1975-08-15 1979-03-13 Philip Morris Incorporated Smoking material
US4148325A (en) 1975-08-18 1979-04-10 British-American Tobacco Company Limited Treatment of tobacco
US4194514A (en) 1976-09-27 1980-03-25 Stauffer Chemical Company Removal of radioactive lead and polonium from tobacco
US4150677A (en) 1977-01-24 1979-04-24 Philip Morris Incorporated Treatment of tobacco
US4237274A (en) 1978-02-24 1980-12-02 Snia Viscosa Societa' Nazionale Industria Applicazioni Viscosa S.P.A. Process for the preparation of solutions of cellulose derivatives which can be coagulated and spun to form regenerated cellulose _bodies
US4268666A (en) 1978-04-03 1981-05-19 Snia Viscosa Societa Nazionale Industria Applicazioni Viscosa S.P.A. Process for the dissolution of cellulose in organic solvents, solutions obtained by said process, and process for the production of formed bodies of regenerated cellulose from said solutions
US4267847A (en) 1978-05-12 1981-05-19 British-American Tobacco Company Limited Tobacco additives
US4252766A (en) 1978-07-27 1981-02-24 Snia Viscosa Societa Nazionale Industria Applicazioni Viscosa S.P.A. Process for the preparation of formed bodies of regenerated cellulose from solutions of cellulose derivatives in dimethylsulphoxide
US4388256A (en) 1978-11-24 1983-06-14 Masamichi Ishida Process for manufacturing regenerated cellulose hollow fiber
US4289147A (en) 1979-11-15 1981-09-15 Leaf Proteins, Inc. Process for obtaining deproteinized tobacco freed of nicotine and green pigment, for use as a smoking product
US4589428A (en) 1980-02-21 1986-05-20 Philip Morris Incorporated Tobacco treatment
US4351346A (en) 1980-03-08 1982-09-28 B.A.T. Cigaretten-Fabriken Gmbh Process for the preparation of aromatic substances
US4359059A (en) 1980-03-08 1982-11-16 B.A.T. Cigaretten-Fabriken Gmbh Process for the preparation of aromatic substances
US4340563A (en) 1980-05-05 1982-07-20 Kimberly-Clark Corporation Method for forming nonwoven webs
US4366823A (en) 1981-06-25 1983-01-04 Philip Morris, Incorporated Process for expanding tobacco
US4366824A (en) 1981-06-25 1983-01-04 Philip Morris Incorporated Process for expanding tobacco
US4388933A (en) 1981-06-25 1983-06-21 Philip Morris, Inc. Tobacco stem treatment and expanded tobacco product
US4535028A (en) 1981-10-01 1985-08-13 Asahi Kasei Kogyo Kabushiki Kaisha Hollow fiber of cuprammonium regenerated cellulose and process for producing the same
US4506682A (en) 1981-12-07 1985-03-26 Mueller Adam Clear tobacco aroma oil, a process for obtaining it from a tobacco extract, and its use
US4725440A (en) 1982-07-02 1988-02-16 E. R. Squibb & Sons, Inc. Antifungal pastille formulation and method
US4660577A (en) 1982-08-20 1987-04-28 R.J. Reynolds Tobacco Company Dry pre-mix for moist snuff
US4605016A (en) 1983-07-21 1986-08-12 Japan Tobacco, Inc. Process for preparing tobacco flavoring formulations
US4641667A (en) 1983-12-09 1987-02-10 B.A.T. Cigarettenfabriken Gmbh Process of preparing nicotine N'-oxide and smoking products containing it
US4622259A (en) 1985-08-08 1986-11-11 Surgikos, Inc. Nonwoven medical fabric
US4716911A (en) 1986-04-08 1988-01-05 Genencor, Inc. Method for protein removal from tobacco
US4727889A (en) 1986-12-22 1988-03-01 R. J. Reynolds Tobacco Company Tobacco processing
US5004595A (en) 1986-12-23 1991-04-02 Warner-Lambert Company Multiple encapsulated flavor delivery system and method of preparation
US5018540A (en) 1986-12-29 1991-05-28 Philip Morris Incorporated Process for removal of basic materials
US4889144A (en) 1987-05-29 1989-12-26 Japan Tobacco Inc. Filter for tobacco smoking
US5005593A (en) 1988-01-27 1991-04-09 R. J. Reynolds Tobacco Company Process for providing tobacco extracts
US5435325A (en) 1988-04-21 1995-07-25 R. J. Reynolds Tobacco Company Process for providing tobacco extracts using a solvent in a supercritical state
US4887618A (en) 1988-05-19 1989-12-19 R. J. Reynolds Tobacco Company Tobacco processing
US6056992A (en) 1988-06-02 2000-05-02 Campbell Soup Company Encapsulated additives
US4967771A (en) 1988-12-07 1990-11-06 R. J. Reynolds Tobacco Company Process for extracting tobacco
US4986286A (en) 1989-05-02 1991-01-22 R. J. Reynolds Tobacco Company Tobacco treatment process
US4941484A (en) 1989-05-30 1990-07-17 R. J. Reynolds Tobacco Company Tobacco processing
US5121757A (en) 1989-12-18 1992-06-16 R. J. Reynolds Tobacco Company Tobacco treatment process
US5060669A (en) 1989-12-18 1991-10-29 R. J. Reynolds Tobacco Company Tobacco treatment process
US5065775A (en) 1990-02-23 1991-11-19 R. J. Reynolds Tobacco Company Tobacco processing
US5131414A (en) 1990-02-23 1992-07-21 R. J. Reynolds Tobacco Company Tobacco processing
US5234008A (en) 1990-02-23 1993-08-10 R. J. Reynolds Tobacco Company Tobacco processing
US5099862A (en) 1990-04-05 1992-03-31 R. J. Reynolds Tobacco Company Tobacco extraction process
US5074319A (en) 1990-04-19 1991-12-24 R. J. Reynolds Tobacco Company Tobacco extraction process
US5668295A (en) 1990-11-14 1997-09-16 Philip Morris Incorporated Protein involved in nicotine synthesis, DNA encoding, and use of sense and antisense DNAs corresponding thereto to affect nicotine content in transgenic tobacco cells and plants
US5131415A (en) 1991-04-04 1992-07-21 R. J. Reynolds Tobacco Company Tobacco extraction process
US5223185A (en) 1991-04-19 1993-06-29 Freund Industrial Co., Ltd. Method of manufacturing seamless capsules and apparatus therefor
US5387093A (en) 1991-05-28 1995-02-07 Freund Inphachem Inc. Apparatus for manufacturing seamless capsules
US5318050A (en) 1991-06-04 1994-06-07 R. J. Reynolds Tobacco Company Tobacco treatment process
US5197494A (en) 1991-06-04 1993-03-30 R.J. Reynolds Tobacco Company Tobacco extraction process
US5343879A (en) 1991-06-21 1994-09-06 R. J. Reynolds Tobacco Company Tobacco treatment process
US5360022A (en) 1991-07-22 1994-11-01 R. J. Reynolds Tobacco Company Tobacco processing
US5148819A (en) 1991-08-15 1992-09-22 R. J. Reynolds Tobacco Company Process for extracting tobacco
US5230354A (en) 1991-09-03 1993-07-27 R. J. Reynolds Tobacco Company Tobacco processing
US5243999A (en) 1991-09-03 1993-09-14 R. J. Reynolds Tobacco Company Tobacco processing
US5301694A (en) 1991-11-12 1994-04-12 Philip Morris Incorporated Process for isolating plant extract fractions
US5441689A (en) 1991-12-02 1995-08-15 Courtaulds Plc Process of making regenerated cellulose articles
US5259403A (en) 1992-03-18 1993-11-09 R. J. Reynolds Tobacco Company Process and apparatus for expanding tobacco cut filler
US5759599A (en) 1992-03-30 1998-06-02 Givaudan Roure Flavors Corporation Method of flavoring and mechanically processing foods with polymer encapsulated flavor oils
US5445169A (en) 1992-08-17 1995-08-29 R. J. Reynolds Tobacco Company Process for providing a tobacco extract
US5387416A (en) 1993-07-23 1995-02-07 R. J. Reynolds Tobacco Company Tobacco composition
US6631722B2 (en) 1993-09-30 2003-10-14 British-American Tobacco Company Limited Tobacco smoke filter elements
US5690990A (en) 1994-03-04 1997-11-25 Arnhem, Inc. Process for encapsulating the flavor with colloid gel matrix
US6077524A (en) 1994-05-06 2000-06-20 Bolder Arzneimittel Gmbh Gastric acid binding chewing pastilles
US5539093A (en) 1994-06-16 1996-07-23 Fitzmaurice; Wayne P. DNA sequences encoding enzymes useful in carotenoid biosynthesis
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5844119A (en) 1994-12-21 1998-12-01 The Salk Institute For Biological Studies Genetically modified plants having modulated flower development
WO1996031255A1 (fr) 1995-04-07 1996-10-10 George Giolvas Procede et appareil pour l'elimination des constituants nocifs des cigarettes et du tabac avant leur consommation
US5997790A (en) 1995-11-20 1999-12-07 Michelin Recherche Et Technique S.A. Process for the preparation of regenerated cellulose filaments
US5882680A (en) 1995-12-07 1999-03-16 Freund Industrial Co., Ltd. Seamless capsule and method of manufacturing the same
US5705624A (en) 1995-12-27 1998-01-06 Fitzmaurice; Wayne Paul DNA sequences encoding enzymes useful in phytoene biosynthesis
US5713376A (en) 1996-05-13 1998-02-03 Berger; Carl Non-addictive tobacco products
US5908032A (en) 1996-08-09 1999-06-01 R.J. Reynolds Tobacco Company Method of and apparatus for expanding tobacco
US6929814B2 (en) 1996-10-09 2005-08-16 Givaudan Sa Process for preparing beads as food additive and product thereof
US6325859B1 (en) 1996-10-09 2001-12-04 Givaudan Roure (International) Sa Process for preparing beads as food or tobacco additive
US6039901A (en) 1997-01-31 2000-03-21 Givaudan Roure Flavors Corporation Enzymatically protein encapsulating oil particles by complex coacervation
US6045835A (en) 1997-10-08 2000-04-04 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
US6106875A (en) 1997-10-08 2000-08-22 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
US6298859B1 (en) 1998-07-08 2001-10-09 Novozymes A/S Use of a phenol oxidizing enzyme in the treatment of tobacco
US6923981B2 (en) 1998-09-25 2005-08-02 Warner-Lambert Company Fast dissolving orally consumable films
US6083527A (en) 1998-11-05 2000-07-04 Thistle; Robert Breath mint with tooth decay and halitosis prevention characteristics
US6131584A (en) 1999-04-15 2000-10-17 Brown & Williamson Tobacco Corporation Tobacco treatment process
US6895974B2 (en) 1999-04-26 2005-05-24 R. J. Reynolds Tobacco Company Tobacco processing
US6482433B1 (en) 1999-06-30 2002-11-19 Givaudan Sa Encapsulation of active ingredients
US6887307B1 (en) 1999-07-22 2005-05-03 Warner-Lambert Company, Llc Pullulan film compositions
US6719933B2 (en) 1999-12-20 2004-04-13 Chugai Seiyaku Kabushiki Kaisha Method for manufacturing seamless capsule
US6510855B1 (en) 2000-03-03 2003-01-28 Brown & Williamson Tobacco Corporation Tobacco recovery system
US20060236434A1 (en) 2000-08-30 2006-10-19 North Carolina State University Methods and compositions for tobacco plants with reduced nicotine
US7230160B2 (en) 2001-03-08 2007-06-12 Michigan State University Lipid metabolism regulators in plants
US6834654B2 (en) 2001-05-01 2004-12-28 Regent Court Technologies, Llc Smokeless tobacco product
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US7208659B2 (en) 2001-05-02 2007-04-24 Conopco Inc. Process for increasing the flavonoid content of a plant and plants obtainable thereby
US6612429B2 (en) 2001-06-22 2003-09-02 Brown & Williamson Tobacco Corporation Flip open package with microencapsulated flavor release
WO2003009711A1 (fr) 2001-07-24 2003-02-06 Jinhee Kim Tabac a gout changeant
US7173170B2 (en) 2001-09-10 2007-02-06 Reynolds Technologies, Inc. High threonine producing lines of Nicotiana tobacum and methods of producing
US6730832B1 (en) 2001-09-10 2004-05-04 Luis Mayan Dominguez High threonine producing lines of Nicotiana tobacum and methods for producing
US6953040B2 (en) 2001-09-28 2005-10-11 U.S. Smokeless Tobacco Company Tobacco mint plant material product
US7032601B2 (en) 2001-09-28 2006-04-25 U.S. Smokeless Tobacco Company Encapsulated materials
US20050123601A1 (en) 2001-11-26 2005-06-09 Jean Mane Capsule for rapid solubilization and release of the content
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
US6772767B2 (en) 2002-09-09 2004-08-10 Brown & Williamson Tobacco Corporation Process for reducing nitrogen containing compounds and lignin in tobacco
US7025066B2 (en) 2002-10-31 2006-04-11 Jerry Wayne Lawson Method of reducing the sucrose ester concentration of a tobacco mixture
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040191322A1 (en) 2002-12-20 2004-09-30 Henri Hansson Physically and chemically stable nicotine-containing particulate material
US7556047B2 (en) 2003-03-20 2009-07-07 R.J. Reynolds Tobacco Company Method of expanding tobacco using steam
US7014039B2 (en) 2003-06-19 2006-03-21 R.J. Reynolds Tobacco Company Sliding shell package for smoking articles
US20040261807A1 (en) 2003-06-23 2004-12-30 Dube Michael Francis Filtered cigarette incorporating a breakable capsule
US20060272663A1 (en) 2003-06-23 2006-12-07 Dube Michael F Filtered cigarette incorporating a breakable capsule
US20090014450A1 (en) 2003-08-18 2009-01-15 Gustavus Ab Snuff-box lid
US7115085B2 (en) 2003-09-12 2006-10-03 R.J. Reynolds Tobacco Company Method and apparatus for incorporating objects into cigarette filters
US7901512B2 (en) 2003-11-03 2011-03-08 U.S. Smokeless Tobacco Company Flavored smokeless tobacco and methods of making
WO2005041699A2 (fr) 2003-11-03 2005-05-12 U.S. Smokeless Tobacco Company Tabac sans fumee aromatise et procedes de fabrication de ce tabac
US20050244521A1 (en) 2003-11-07 2005-11-03 Strickland James A Tobacco compositions
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
WO2005063060A1 (fr) 2003-12-22 2005-07-14 U.S. Smokeless Tobacco Company Procede de traitement pour compositions de tabac ou de tabac a priser
US7694686B2 (en) 2003-12-22 2010-04-13 U.S. Smokeless Tobacco Company Conditioning process for tobacco and/or snuff compositions
US20060228308A1 (en) 2004-02-26 2006-10-12 Cummins Barry W Oral health care drink and method for reducing malodors
US20050196437A1 (en) 2004-03-02 2005-09-08 Bednarz Christina A. Hard capsules
US20050249676A1 (en) 2004-05-04 2005-11-10 Robert Scott Pullulan capsules
US20080196730A1 (en) 2004-07-02 2008-08-21 Radi Medical Systems Ab Smokeless Tobacco Product
US7337782B2 (en) 2004-08-18 2008-03-04 R.J. Reynolds Tobacco Company Process to remove protein and other biomolecules from tobacco extract or slurry
US7798153B2 (en) 2004-08-23 2010-09-21 Us Smokeless Tobacco Co. Nicotiana Kawakamii smokeless tobacco
US7650892B1 (en) 2004-09-03 2010-01-26 Rosswil Llc Ltd. Methods for hindering formation of tobacco-specific nitrosamines
US20060130961A1 (en) 2004-12-17 2006-06-22 Byrne Thomas T Method and apparatus for splicing a web material
US20060144412A1 (en) 2004-12-30 2006-07-06 Philip Morris Usa Inc. Encapsulated additives and methods of making encapsulated additives
US20060174901A1 (en) 2005-02-04 2006-08-10 Philip Morris Usa Inc. Flavor capsule for enhanced flavor delivery in cigarettes
US20060210488A1 (en) 2005-03-19 2006-09-21 Jakubowski Henryk P Teeth whitening candy with tartar removal and breath freshening properties
US20070012327A1 (en) 2005-05-03 2007-01-18 Philip Morris Usa Inc. Cigarettes and filter subassemblies with squeezable flavor capsule and methods of manufacture
US7537110B2 (en) 2005-06-02 2009-05-26 Philip Morris Usa Inc. Container for consumer article
WO2007010407A2 (fr) 2005-06-21 2007-01-25 V. Mane Fils Dispositif pour fumeur incorporant une capsule frangible, capsule frangible et procede de fabrication de ladite capsule
WO2006136197A1 (fr) 2005-06-21 2006-12-28 V. Mane Fils Produit a fumer comprenant une capsule cassante, capsule cassante et procede de fabrication de cette capsule
WO2006136199A1 (fr) 2005-06-21 2006-12-28 V.Mane Fils Article pour fumeur contenant une capsule frangible, capsule frangible et procede de fabrication associe
US7584843B2 (en) 2005-07-18 2009-09-08 Philip Morris Usa Inc. Pocket-size hand-held container for consumer items
WO2007060543A2 (fr) 2005-08-15 2007-05-31 Philip Morris Products S.A. Dispositif de liberation de liquide destine a un article pour fumeur
WO2007037962A1 (fr) 2005-09-22 2007-04-05 R.J. Reynolds Tobacco Company Composition de tabac qui ne se fume pas
EP1926401A1 (fr) * 2005-09-22 2008-06-04 R.J.Reynolds Tobacco Company Composition de tabac qui ne se fume pas
US20070062549A1 (en) 2005-09-22 2007-03-22 Holton Darrell E Jr Smokeless tobacco composition
US20070068540A1 (en) 2005-09-23 2007-03-29 Thomas Timothy F Equipment for insertion of objects into smoking articles
US20070095357A1 (en) 2005-11-01 2007-05-03 Philip Morris Usa Inc. Smoking article with manually releasable odorant
US7819124B2 (en) 2006-01-31 2010-10-26 U.S. Smokeless Tobacco Company Tobacco articles and methods
US7810507B2 (en) 2006-02-10 2010-10-12 R. J. Reynolds Tobacco Company Smokeless tobacco composition
US7861728B2 (en) 2006-02-10 2011-01-04 R.J. Reynolds Tobacco Company Smokeless tobacco composition having an outer and inner pouch
US20080029110A1 (en) * 2006-02-10 2008-02-07 R. J. Reynolds Tobacco Company Smokeless Tobacco Composition
WO2007104573A2 (fr) 2006-03-16 2007-09-20 Niconovum Ab Composition améliorée de tabac à priser
US20080173317A1 (en) 2006-08-01 2008-07-24 John Howard Robinson Smokeless tobacco
US20100084424A1 (en) 2006-12-12 2010-04-08 John Gelardi Container with pivoting cover
US8177938B2 (en) 2007-01-19 2012-05-15 Georgia-Pacific Consumer Products Lp Method of making regenerated cellulose microfibers and absorbent products incorporating same
WO2008103935A2 (fr) 2007-02-23 2008-08-28 U.S. Smokeless Tobacco Company Nouvelles compositions de tabac et leurs procédés de fabrication
US20100101588A1 (en) 2007-03-20 2010-04-29 Azionaria Costruzioni Macchine Automatiche A.C.M.A S.P.A. Machine for manufacturing pouches of cohesionless material
US8186360B2 (en) 2007-04-04 2012-05-29 R.J. Reynolds Tobacco Company Cigarette comprising dark air-cured tobacco
US20090014343A1 (en) 2007-05-07 2009-01-15 Philip Morris Usa Inc. Pocket-size hybrid container for consumer items
US20080302377A1 (en) 2007-06-05 2008-12-11 Michail Kassymovich Nauryzbaev Method for extraction of nicotine from tobacco raw material
US20080305216A1 (en) 2007-06-08 2008-12-11 Philip Morris Usa Inc. Capsule clusters for oral consumption
US8061362B2 (en) 2007-07-23 2011-11-22 R. J. Reynolds Tobacco Company Smokeless tobacco composition
US9237769B2 (en) 2007-07-23 2016-01-19 R. J. Reynolds Tobacco Company Smokeless tobacco composition
USD594154S1 (en) 2007-11-13 2009-06-09 R.J. Reynolds Tobacco Company Container with bottom compartment
US20090293889A1 (en) 2007-11-28 2009-12-03 Philip Morris Usa Inc. Smokeless compressed tobacco product for oral consumption
US20090250360A1 (en) 2007-11-30 2009-10-08 Philip Morris Usa Inc. Pocket-size container for consumer items
USD592956S1 (en) 2008-02-08 2009-05-26 Philip Morris Usa Inc. Container
US20090230003A1 (en) 2008-02-08 2009-09-17 Philip Morris Usa Inc. Pocket-sized container
US20090223989A1 (en) 2008-03-04 2009-09-10 R.J. Reynolds Tobacco Company Dispensing Container
US8096339B2 (en) 2008-03-27 2012-01-17 Herrmann Ultraschalltechnik Gmbh & Co. Kg Ultrasonic welding tool with fluid drive
US20090266837A1 (en) 2008-04-25 2009-10-29 R. J. Reynolds Tobacco Company Dispensing Container
US20100018539A1 (en) 2008-07-28 2010-01-28 Paul Andrew Brinkley Smokeless tobacco products and processes
US20100133140A1 (en) 2008-12-01 2010-06-03 Bailey Ryan A Dual cavity sliding dispenser
US20100291245A1 (en) 2008-12-08 2010-11-18 Philip Morris Usa Inc. Soft, chewable and orally dissolvable and/or disintegrable products
US20120067361A1 (en) 2009-04-03 2012-03-22 X-International Aps Plant fiber product and method for its manufacture
USD625178S1 (en) 2009-04-16 2010-10-12 R.J. Reynolds Tobacco Company, Inc. Container with hinged insert
US20100264157A1 (en) 2009-04-16 2010-10-21 R.J. Reynolds Tobacco Company Dispensing container for metered dispensing of product
US8557071B2 (en) 2009-04-27 2013-10-15 Herrmann Ultraschalltechnik Gmbh & Co. Kg Ultrasound welding device and method for welding material webs
WO2010132444A2 (fr) 2009-05-11 2010-11-18 U.S. Smokeless Tobacco Company Llc Procédé et dispositif pour aromatiser du tabac sans fumée
US11246334B2 (en) 2009-05-11 2022-02-15 Altria Client Services Llc Method and device for flavoring smokeless tobacco
US8434496B2 (en) 2009-06-02 2013-05-07 R. J. Reynolds Tobacco Company Thermal treatment process for tobacco materials
US8944072B2 (en) 2009-06-02 2015-02-03 R.J. Reynolds Tobacco Company Thermal treatment process for tobacco materials
US8991403B2 (en) 2009-06-02 2015-03-31 R.J. Reynolds Tobacco Company Thermal treatment process for tobacco materials
US20120085360A1 (en) 2009-06-16 2012-04-12 Norio Kawata Oral tobacco product
US20110139164A1 (en) 2009-12-15 2011-06-16 R. J. Reynolds Tobacco Company Tobacco Product And Method For Manufacture
US20110168712A1 (en) 2010-01-12 2011-07-14 R.J. Reynolds Tobacco Company Dispensing container
US8397945B2 (en) 2010-02-23 2013-03-19 R.J. Reynolds Tobacco Company Dispensing container
US20110247640A1 (en) 2010-04-08 2011-10-13 R. J. Reynolds Tobacco Company Smokeless Tobacco Composition Comprising Tobacco-Derived Material and Non-Tobacco Plant Material
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20120037175A1 (en) 2010-08-11 2012-02-16 R.J. Reynolds Tobacco Company Meltable smokeless tobacco composition
US20120055493A1 (en) 2010-09-02 2012-03-08 R.J. Reynolds Tobacco Company Apparatus for manufacturing a smokeless tobacco product incorporating an object, and associated method
US20120055494A1 (en) 2010-09-07 2012-03-08 Rj Reynolds Tobacco Company Smokeless Tobacco Product Comprising Effervescent Composition
US20120103353A1 (en) 2010-11-01 2012-05-03 Sebastian Andries D Smokeless tobacco products
US8931493B2 (en) 2010-11-01 2015-01-13 R.J. Reynolds Tobacco Co. Smokeless tobacco products
US20120138074A1 (en) 2010-12-01 2012-06-07 Rj Reynolds Tobacco Company Smokeless tobacco pastille and moulding process for forming smokeless tobacco products
US20120138073A1 (en) 2010-12-01 2012-06-07 Rj Reynolds Tobacco Company Smokeless tobacco pastille and injection molding process for forming smokeless tobacco products
US20130074856A1 (en) 2011-09-22 2013-03-28 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130074855A1 (en) 2011-09-22 2013-03-28 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130152953A1 (en) 2011-12-14 2013-06-20 R. J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
WO2013122948A1 (fr) 2012-02-13 2013-08-22 R. J. Reynolds Tobacco Company Composition de tabac blanchi
US9420825B2 (en) 2012-02-13 2016-08-23 R.J. Reynolds Tobacco Company Whitened tobacco composition
US20130274296A1 (en) 2012-04-17 2013-10-17 R.J. Reynolds Tobacco Company Remelted ingestible products
US9339058B2 (en) 2012-04-19 2016-05-17 R. J. Reynolds Tobacco Company Method for producing microcrystalline cellulose from tobacco and related tobacco product
US20140083438A1 (en) 2012-09-21 2014-03-27 R.J. Reynolds Tobacco Company Fibrous composite tobacco-containing materials
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US20150068545A1 (en) 2013-09-09 2015-03-12 R.J. Reynolds Tobacco Company Smokeless tobacco composition incorporating a botanical material
US20150101627A1 (en) 2013-10-16 2015-04-16 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
US20150230515A1 (en) 2014-02-14 2015-08-20 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
US20170112183A1 (en) 2014-04-04 2017-04-27 X-International Aps Tobacco Raw Material
US20170020183A1 (en) 2014-04-04 2017-01-26 X-International Aps Tobacco Raw Material
US20160000140A1 (en) 2014-07-02 2016-01-07 R.J. Reynolds Tobacco Company Oral pouch products
US20160073689A1 (en) 2014-09-12 2016-03-17 R.J. Reynolds Tobacco Company Nonwoven pouch comprising heat sealable binder fiber
US20160073686A1 (en) 2014-09-12 2016-03-17 R.J. Reynolds Tobacco Company Tobacco-derived filter element
US11344057B2 (en) 2014-12-05 2022-05-31 R.J. Reynolds Tobacco Company Capsule-containing pouched product for oral use
US20160157515A1 (en) * 2014-12-05 2016-06-09 R.J. Reynolds Tobacco Company Smokeless tobacco pouch
US9950858B2 (en) 2015-01-16 2018-04-24 R.J. Reynolds Tobacco Company Tobacco-derived cellulose material and products formed thereof
WO2018083114A1 (fr) 2016-11-02 2018-05-11 Winnington Ab Substance de tabac défibré
US20200331884A1 (en) 2017-12-22 2020-10-22 Siegfried Ag Preparation of racemic nicotine by reaction of ethyl nicotinate with n-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps
US10913962B2 (en) 2018-11-16 2021-02-09 Zanoprima Lifesciences Limited Process of making (S)-nicotine
WO2020128971A1 (fr) 2018-12-20 2020-06-25 R. J. Reynolds Tobacco Company Procédé de blanchiment de tabac
WO2021048768A1 (fr) 2019-09-11 2021-03-18 Nicoventures Trading Limited Procédé de blanchiment de tabac
WO2021048770A1 (fr) 2019-09-11 2021-03-18 Nicoventures Trading Limited Procédés alternatifs de blanchiment du tabac
US20220071984A1 (en) 2019-09-11 2022-03-10 Nicoventures Trading Limited Oral product with nicotine and ion pairing agent
WO2021048769A1 (fr) 2019-09-13 2021-03-18 Nicoventures Trading Limited Procédé de blanchiment de tabac
WO2021058063A2 (fr) 2019-09-23 2021-04-01 Polysecure Gmbh Procédé de tri
US20210169792A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral compositions and methods of manufacture
US20210169132A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral composition including gels
US20210177754A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Nanoemulsion for oral use
US20210177043A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product
US20210177038A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral products with active ingredient combinations
US20210186081A1 (en) 2019-12-09 2021-06-24 Nicoventures Trading Limited Pouched oral product with cannabinoid
US20210330590A1 (en) 2019-12-09 2021-10-28 Nicoventures Trading Limited Agents for oral composition
US20210169867A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Moist oral compositions
US20210169122A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral foam composition
US20210169121A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Liquid oral composition
US20210378948A1 (en) 2020-06-08 2021-12-09 Nicoventures Trading Limited Effervescent oral composition
US20220160675A1 (en) 2020-11-25 2022-05-26 Nicoventures Trading Limited Oral cannabinoid product with lipid component

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Tobacco Production, Chemistry and Technology", 1999
ASAWAHAME, CHAWALINEE ET AL.: "Formation of Orally Fast Dissolving Fibers Containing Propolis by Electrospinning Technique", CHIANG MAI J. SCI., vol. 42, no. 2, 2015, pages 469 - 480
DVORYANCHIKOV ET AL., J NEUROSCI, vol. 31, no. 15, 13 April 2011 (2011-04-13), pages 5782 - 91
FLORENCE L. WAGNER ET AL., TETRAHEDRON, vol. 63, 2007, pages 8065
GUTCHO, MICROCAPSULES AND MICROENCAPSULATION TECHNIQUES, 1976
GUTCHO, MICROCAPSULES AND OTHER CAPSULES ADVANCES SINCE, 1975
IWAMOTO ET AL., AAPS PHARM. SCI. TECH., vol. 3, no. 3, 2002
KONDO, MICROCAPSULE PROCESSING AND TECHNOLOGY, 1979
LEFFINGWELL ET AL.: "Tobacco Flavoring for Smoking Products", 1972, R. J. REYNOLDS TOBACCO COMPANY
NESTOR ET AL., BEITRAGE TABAKFORSCH. INT., vol. 20, 2003, pages 467 - 475
PERFETTI, BEITRAGE TABAKFORSCHUNG INT., vol. 12, 1983, pages 43 - 54
SANTHOSH ET AL., PHYTOMEDICINE, vol. 12, 2005, pages 216 - 220
STAAF ET AL., BEITRAGE TABAKFORSCH. INT., vol. 21, 2005, pages 321 - 330
TAKAHASHI ET AL., ORAL MICROBIOLOGY AND IMMUNOLOGY, vol. 19, no. 1, 2004, pages 61 - 64
THE EFSA JOURNAL, vol. 85, 2004, pages 1 - 32

Similar Documents

Publication Publication Date Title
US20210206554A1 (en) Oral product with dissolvable component
US20210204590A1 (en) Pouched products
US20220225660A1 (en) Pouched products with heat sealable binder
US20220304373A1 (en) Fibrous fleece material
US20210204585A1 (en) Pouched products with heat sealable binder
US20210169790A1 (en) Fleece for oral product with releasable component
US20220346436A1 (en) Orally dissolving films
JP2023505527A (ja) 香味の持続放出を有する経口製品
US20210251276A1 (en) Layered fleece for pouched product
US20230049343A1 (en) Shaped pouched products
WO2024079722A1 (fr) Produits en sachet contenant des capsules
US20230148652A1 (en) Oral products with nicotine-polymer complex
US20230148660A1 (en) Products with enhanced sensory characteristics
WO2024089588A1 (fr) Produits en forme de sachet
US20220400744A1 (en) Pouched product comprising dissolvable composition
US20220354155A1 (en) Multi-compartment oral pouched product
WO2024095164A1 (fr) Produits à charge sphérique
WO2024095163A1 (fr) Composition orale comprenant un agent d'ajustement de ph encapsulé
WO2023194959A1 (fr) Produits en sachet avec liant thermoscellable

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23793069

Country of ref document: EP

Kind code of ref document: A1